P2x4 receptor antagonist

ABSTRACT

A diazepine derivative having the following formula (III) or a pharmacologically acceptable salt thereof is used as A P2X 4  receptor antagonist: 
     
       
         
         
             
             
         
       
         
         
           
             wherein each of R 21  and R 22  is hydrogen, a C 1-8  alkyl group or the like; 
             R 23  is hydrogen, a C 1-8  alkyl group or the like; 
             each of R 24  and R 25  is hydrogen, a C 1-8  alkyl group or the like; 
             R 26  is hydrogen, a C 1-8  alkyl group, a halogen atom, hydroxyl, nitro, cyano, phenyl optionally having one or more substituents, or a heterocyclic group optionally having one or more substituents or the like; and 
             p is 0 or 1.

FIELD OF THE INVENTION

The present invention relates to a diazepine derivative showing P2X₄ receptor antagonism.

BACKGROUND OF THE INVENTION

ATP receptors are basically classified into P2X family of ion-channel type receptors and P2Y family of G protein-coupled receptors. Until now, there are reported, respectively, seven sub-types (P2X₁₋₇) and eight sub-types (P2Y_(1, 2, 4, 6, 11-14)).

It has been reported that P2X₄ receptor (Genebank No. X87763), which is a sub-type of P2X family, is present widely in the central nervous systems (cf. Non-patent documents 1-5).

The mechanism of pathogenesis of intractable pains such as neuropathic pain is unclear. Therefore, if non-steroidal anti-inflammatory drugs (NSAIDs) and morphine are not effective, there is no other pharmacotherapy. In that case, the patient and surrounding people take up a heavy burden in mind and body. The neuropathic pain is caused by injury of peripheral or central nervous systems, for instance, post-surgery pain, cancer, spinal cord injury, herpes zoster, diabetic neuritis, or trigeminal neuralgia.

Recently, Inoue, et al. studied the involvement of P2X receptors in neuropathic pain using dorsal root ganglion neuron-injured animal model, which induces allodynia, and indicated that the nerve-injured pain (particularly, allodynia) is caused via P2X₄ receptors on spinal microglia (cf. Non-patent documents 6, 7, and Patent document 1).

Accordingly, compounds that inhibit the action of P2X₄ receptors are expected to be employed for preventing or treating nociceptive, inflammatory, and neuropathic pains.

Patent document 2 discloses that benzofuro-1,4-diazepin-2-one derivatives having the below-illustrated formula (A) show P2X₄ receptor antagonism:

wherein R₁ is halogen, and R₂ is hydrogen, halogen, nitro, cyano, C(O)—OR₃, C(O)—NR₄R₅, SO₂—OR₃, or SO₂—NR₄R₅, or in which R¹ is hydrogen, and R₂ is halogen, nitro, cyano, C(O)—OR₃, C(O)—NR₄R₅, SO₂—OR₃, or SO₂—NR₄R₅.

Non-patent document 8 discloses that Paroxetine known as an antidepressant also shows P2X₄ receptor antagonism.

The present inventors have found that naphtho[1,2-e]-1,4-diazepin-2-on derivatives having the below-illustrated formula (B) showing P2X₄ receptor antagonism, and filed the Patent document 3.

Patent document 4 discloses a naphtho[1,2-b]-1,4-diazepin-4-on derivative represented by the following formula (C).

Patent document 4 describes that the compound represented by the formula (C) can be used as photographic couplers. Patent document 4, however, is silent with respect to the relation between the compound and the P2X₄ receptor antagonism.

Non-patent document 9 discloses a naphtho[1,2-e]-1,4-diazepin-2-on derivative represented by the following formula.

Non-patent document 9, however, is silent with respect to the relation between the compound and the P2X₄ receptor antagonism.

PRIOR ART DOCUMENTS Patent Documents

-   Patent document 1: United States patent publication No. 20050074819 -   Patent document 2: WO 2004/085440 -   Patent document 3: WO 2008/023847 -   Patent document 4: Japanese Patent Publication No. 2 (1990)-304437

Non-Patent Documents

-   Non-patent document 1: Buell, et al. (1996) EMBO J. 15: 55-62 -   Non-patent document 2: Seguela, et al. (1996) J. Neurosci. 16:     448-455 -   Non-patent document 3: Bo, et al. (1995) FEBS Lett. 375: 129-133 -   Non-patent document 4: Soto, et al. (1996) Proc. Natl. Acad. Sci.     USA 93: 3684-3788 -   Non-patent document 5: Wang, et al. (1996) Biochem. Res. Commun.     220: 196-202 -   Non-patent document 6: M. Tsuda, et al. (2003) Nature, 424, 778-783 -   Non-patent document 7: Jeffrey A. M. Coull, et al. (2005) Nature,     438, 1017-1021 -   Non-patent document 8: Paper Abstract of Lecture Program P3-N-114,     The 49th Annual Meeting of Japanese Society for Neurochemistry     (2006) -   Non-patent document 9: Journal of Heterocyclic Chemistry (1976),     13(4), 813-19

SUMMARY OF THE INVENTION Problems to be Solved by the Invention

It is the object of the present invention to provide a diazepine derivative represented by the formula (I), which shows P2X₄ receptor antagonism.

Means for Solving the Problems

The present invention relates to a diazepine derivative having the following formula (I) or a pharmacologically acceptable salt thereof:

wherein each of R¹ and R² independently is hydrogen, a C₁₋₈ alkyl group, a C₂₋₈ alkenyl group, a C₁₋₈ alkoxy group, a C₁₋₈ alkyl group having one to three halogen atoms, a C₁₋₈ alkoxy group having one to three halogen atoms, a halogen atom, hydroxyl, nitro, cyano, amino, a C₁₋₈ alkylamino group, a C₂₋₈ dialkylamino group, a C₂₋₈ acylamino group, a C₂₋₈ acylamino group having one to three halogen atoms, a C₁₋₈ alkylsulfonylamino group, carboxyl, a C₂₋₈ acyl group, an alkoxycarbonyl group comprising a C₁₋₈ alkoxy moiety, carbamoyl, a C₁₋₈ alkylthio group, a C₁₋₈ alkylsulfinyl group, a C₁₋₈ alkylsulfonyl group, or sulfamoyl;

R³ is hydrogen, a C₁₋₈ alkyl group, a C₂₋₈ alkenyl group, a C₁₋₈ alkyl group having one to three halogen atoms, or a C₁₋₃ alkyl group having phenyl;

each of R⁴ and R⁵ independently is hydrogen, a C₁₋₈ alkyl group, a C₁₋₈ alkyl group having one to three halogen atoms, a halogen atom, hydroxyl, nitro, cyano, amino, or a C₁₋₃ alkyl group having phenyl;

R⁶ is hydrogen, a C₁₋₈ alkyl group, a C₂₋₈ alkenyl group, a C₁₋₈ alkoxy group, a C₁₋₈ alkyl group having one to three halogen atoms, a C₁₋₈ alkoxy group having one to three halogen atoms, a halogen atom, hydroxyl, nitro, cyano, amino, a C₁₋₈ alkylamino group, a C₂₋₈ dialkylamino group, a C₂₋₈ acylamino group, a C₂₋₈ acylamino group having one to three halogen atoms, a C₁₋₈ alkylsulfonylamino group, carboxyl, a C₂₋₈ acyl group, an alkoxycarbonyl group comprising a C₁₋₈ alkoxy moiety, carbamoyl, a C₁₋₈ alkylthio group, a C₁₋₈ alkylsulfinyl group, a C₁₋₈ alkylsulfonyl group, sulfamoyl, phenyl optionally having one or more substituents, or a heterocyclic group optionally having one or more substituents;

the ring shown below is a five-membered to eight-membered non-aromatic ring optionally comprising one or two heteroatoms selected from N, S, and O, and being condensed with the benzene ring at the positions of 1 and 2 of the benzene ring;

the ring shown below is an aromatic ring selected from the group consisting of benzene ring, naphthalene ring, thiophene ring, pyridine ring, pyrimidine ring, indole ring, indazole ring, benzotriazole ring, benzisoxazole ring, benzimidazole ring, and quinoline ring;

Z is O or S;

when X is N, Y is C═O or C═S, and the double line consisting of a solid line and a broken line is a single bond; and

when X is C, Y is N, and the double line consisting of a solid line and a broken line is a double bond.

The invention also relates to a diazepine derivative having the following formula (II) or a pharmacologically acceptable salt thereof:

wherein each of R¹¹ and R¹² independently is hydrogen, a C₁₋₈ alkyl group, a C₂₋₈ alkenyl group, a C₁₋₈ alkoxy group, a C₁₋₈ alkyl group having one to three halogen atoms, a C₁₋₈ alkoxy group having one to three halogen atoms, a halogen atom, hydroxyl, nitro, cyano, amino, a C₁₋₈ alkylamino group, a C₂₋₈ dialkylamino group, a C₂₋₈ acylamino group, a C₂₋₈ acylamino group having one to three halogen atoms, a C₁₋₈ alkylsulfonylamino group, carboxyl, a C₂₋₈ acyl group, an alkoxycarbonyl group comprising a C₁₋₈ alkoxy moiety, carbamoyl, a C₁₋₈ alkylthio group, a C₁₋₈ alkylsulfinyl group, a C₁₋₈ alkylsulfonyl group, or sulfamoyl;

R¹³ is hydrogen, a C₁₋₈ alkyl group, a C₂₋₈ alkenyl group, a C₁₋₈ alkyl group having one to three halogen atoms, or a C₁₋₃ alkyl group having phenyl;

each of R¹⁴ and R¹⁵ independently is hydrogen, a C₁₋₈ alkyl group, a C₁₋₈ alkyl group having one to three halogen atoms, a halogen atom, hydroxyl, nitro, cyano, amino, or a C₁₋₃ alkyl group having phenyl;

R¹⁶ is hydrogen, a C₁₋₈ alkyl group, a C₂₋₈ alkenyl group, a C₁₋₈ alkoxy group, a C₁₋₈ alkyl group having one to three halogen atoms, a C₁₋₈ alkoxy group having one to three halogen atoms, a halogen atom, hydroxyl, nitro, cyano, amino, a C₁₋₈ alkylamino group, a C₂₋₈ dialkylamino group, a C₂₋₈ acylamino group, a C₂₋₈ acylamino group having one to three halogen atoms, a C₁₋₈ alkylsulfonylamino group, carboxyl, a C₂₋₈ acyl group, an alkoxycarbonyl group comprising a C₁₋₈ alkoxy moiety, carbamoyl, a C₁₋₈ alkylthio group, a C₁₋₈ alkylsulfinyl group, a C₁₋₈ alkylsulfonyl group, sulfamoyl, phenyl optionally having one or more substituents, or a heterocyclic group optionally having one or more substituents;

the ring shown below is a five-membered to eight-membered non-aromatic ring optionally comprising one or two heteroatoms selected from N, S, and O, and being condensed with the benzene ring at the positions of 1 and 2 of the benzene ring;

the ring shown below is an aromatic ring selected from the group consisting of benzene ring, naphthalene ring, thiophene ring, pyridine ring, pyrimidine ring, indole ring, indazole ring, benzotriazole ring, benzisoxatole ring, benzimidazole ring, and quinoline ring; and

each of Z¹ and Z² independently is C or S.

The invention further relates to a diazepine derivative having the following formula (III) or a pharmacologically acceptable salt thereof:

wherein each of R²¹ and R²² independently is hydrogen, a C₁₋₈ alkyl group, a C₂₋₈ alkenyl group, a C₁₋₈ alkoxy group, a C₁₋₈ alkyl group having one to three halogen atoms, a C₁₋₈ alkoxy group having one to three halogen atoms, a halogen atom, hydroxyl, nitro, cyano, amino, a C₁₋₈ alkylamino group, a C₂₋₈ dialkylamino group, a C₂₋₈ acylamino group, a C₂₋₈ acylamino group having one to three halogen atoms, a C₁₋₈ alkylsulfonylamino group, carboxyl, a C₂₋₈ acyl group, an alkoxycarbonyl group comprising a C₁₋₈ alkoxy moiety, carbamoyl, a C₁₋₈ alkylthio group, a C₁₋₈ alkylsulfinyl group, a C₁₋₈ alkylsulfonyl group, or sulfamoyl;

R²³ is hydrogen, a C₁₋₈ alkyl group, a C₂₋₈ alkenyl group, a C₁₋₈ alkyl group having one to three halogen atoms, or a C₁₋₃ alkyl group having phenyl;

each of R²⁴ and R²⁵ independently is hydrogen, a C₁₋₈ alkyl group, a C₁₋₈ alkyl group having one to three halogen atoms, a halogen atom, hydroxyl, nitro, cyano, amino, or a C₁₋₃ alkyl group having phenyl;

R²⁶ is hydrogen, a C₁₋₈ alkyl group, a C₂₋₈ alkenyl group, a C₁₋₈ alkoxy group, a C₁₋₈ alkyl group having one to three halogen atoms, a C₁₋₈ alkoxy group having one to three halogen atoms, a halogen atom, hydroxyl, nitro, cyano, amino, a C₁₋₈ alkylamino group, a C₂₋₈ dialkylamino group, a C₂₋₈ acylamino group, a C₂₋₈ acylamino group having one to three halogen atoms, a C₁₋₈ alkylsulfonylamino group, carboxyl, a C₂₋₈ acyl group, an alkoxycarbonyl group comprising a C₁₋₈ alkoxy moiety, carbamoyl, a C₁₋₈ alkylthio group, a C₁₋₈ alkylsulfinyl group, a C₁₋₈ alkylsulfonyl group, sulfamoyl, phenyl optionally having one or more substituents, or a heterocyclic group optionally having one or more substituents; and

p is 0 or 1.

The invention also relates to a P2X₄ receptor antagonist containing a compound represented by the formula (I), (II), or (III), or its pharmacologically acceptable salt as an active ingredient.

The invention further relates to a preventive or therapeutic agent for neuropathic pains containing a compound represented by the formula (I), (II), or (III), or its pharmacologically acceptable salt as an active ingredient. The embodiments of the invention

The present invention is described below in more detail.

In the compound of the present invention represented by the formula (I), the alkyl group having 1 to 8 carbon atoms for R¹, R², R³, R⁴, R⁵, and R⁶ can be methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, or hexyl.

The alkenyl group having 2 to 8 carbon atoms for R¹, R², R³, and R⁶ can be allyl.

The alkyl group having 1 to 8 carbon atoms substituted with 1 to 3 halogen atoms for R¹, R², R³, R⁴, R⁵, and R⁶ can be methyl, ethyl, propyl, isopropyl, butyl, or t-butyl substituted with 1 to 3 halogen atoms such as 1 to 3 fluoro, chloro, or bromo atoms, and preferably is trifluoromethyl, chloromethyl, 2-chloroethyl, 2-bromoethyl, or 2-fluoroethyl.

The alkyl group having 1 to 3 carbon atoms substituted with phenyl for R³, R⁴, and R⁵ can be benzyl.

The alkoxy group having 1 to 8 carbon atoms for R¹, R², and R⁶ can be methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, t-butoxy, pentyloxy, or hexyloxy.

The alkoxy group having 1 to 8 carbon atoms substituted with 1 to 3 halogen atoms for R₁, R², and R⁶ can be methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, or t-butoxy substituted with 1 to 3 halogen atoms such as 1 to 3 fluoro, chloro, or bromo atoms, and preferably include trifluoromethoxy, chloromethoxy, 2-chloroethoxy, 2-bromoethoxy, or 2-fluoroethoxy.

The halogen atom for R¹, R², R⁴, R⁵, and R⁶ can be fluoro, chloro, or bromo atom.

The alkylamino group having 1 to 8 carbon atoms for R¹, R², and R⁶ can be methylamino or ethylamino.

The dialkylamino group having 2 to 8 carbon atoms for R¹, R², and R⁶ can be dimethylamino or diethylamino.

The acylamino group having 2 to 8 carbon atoms for R¹, R², and R⁶ can be acetylamino.

The acylamino group having 2 to 8 carbon atoms substituted with 1 to 3 halogen atoms for R¹, R², and R⁶ can be trifluoromethylcarbonylamino.

The alkylsulfonylamino group having 1 to 8 carbon atoms for R¹, R², and R⁶ can be methylsulfonylamino.

The acyl group having 2 to 8 carbon atoms for R¹, R², and R⁶ can be acetyl.

The alkoxycarbonyl group comprising an alkoxy moiety having 1 to 8 carbon atoms for R¹, R², and R⁶ can be methoxycarbonyl, or ethoxycarbonyl.

The alkylthio group having 1 to 8 carbon atoms for R¹, R², and R⁶ can be methylthio.

The alkylsulfinyl group having 1 to 8 carbon atoms for R¹, R², and R⁶ can be methylsulfinyl.

The alkylsulfonyl group having 1 to 8 carbon atoms for R¹, R², and R⁶ can be methylsulfonyl.

With respect to the phenyl optionally having one or more substituents for R⁶, the substituent preferably is an alkyl group having 1 to 8 carbon atoms (such as methyl, ethyl), an alkyl group having 1 to 8 carbon atoms substituted with 1 to 3 halogen atoms (such as trifluoromethyl), a halogen atom (such as fluoro atom), and cyano. The heterocyclic group optionally having one or more substituents for R⁶ preferably is tetrazolyl, triazolyl, pyridyl, imidazolyl, oxazolyl, or triazolyl. The heterocyclic group can also be oxadiazolyl.

With respect to the heterocyclic group optionally having one or more substituents for R⁶, the substituent preferably is an alkyl group having 1 to 8 carbon atoms (e.g., methyl, ethyl), an alkyl group having 1 to 8 carbon atoms substituted with 1 to 3 halogen atoms (such as trifluoromethyl), a halogen atom (such as fluoro atom), cyano, and oxo. The substituent can also be phenyl.

The ring shown below can be tetrahydronaphthalene, indan, indoline, tetrahydroquinoline, or tetrahydroisoquinoline.

R¹, R², and R⁶ in the formula (I) can be the same or different two or more substituents attached to the rings to which R¹, R², and R⁶ are attached.

Examples of R¹¹ to R¹⁶ in the formula (II) and R²¹ to R²⁶ in the formula (III) are the same as the examples of the alkyl group having 1 to 8 carbon atoms, the alkenyl group having 2 to 8 carbon atoms, the alkyl group having 1 to 8 carbon atoms substituted with 1 to 3 halogen atoms, the alkyl group having 1 to 3 carbon atoms substituted with phenyl, the alkoxy group having 1 to 8 carbon atoms, the alkoxy group having 1 to 8 carbon atoms substituted with 1 to 3 halogen atoms, the halogen atom, the alkylamino group having 1 to 8 carbon atoms, the dialkylamino group having 2 to 8 carbon atoms, the acylamino group having 2 to 8 carbon atoms, the acylamino group having 2 to 8 carbon atoms substituted with 1 to 3 halogen atoms, the alkylsulfonylamino group having 1 to 8 carbon atoms, the acyl group having 2 to 8 carbon atoms, the alkoxycarbonyl group comprising an alkoxy moiety having 1 to 8 carbon atoms, the alkylthio group having 1 to 8 carbon atoms, the alkylsulfinyl group having 1 to 8 carbon atoms, the alkylsulfonyl group having 1 to 8 carbon atoms, the phenyl optionally having one or more substituents, and the heterocyclic group optionally having one or more substituents for R¹ to R⁶ in the formula (I).

With respect to the heterocyclic group optionally having one or more substituents for R¹⁶ in the formula (II) and R²⁶ in the formula (III), the examples of the substituents are the same as the examples of the alkyl group having 1 to 8 carbon atoms, the alkyl group having 1 to 8 carbon atoms substituted with 1 to 3 halogen atoms, the halogen atoms, the alkylamino group having 1 to 8 carbon atoms, and the dialkylamino group having 2 to 8 carbon atoms for R¹ to R⁶ in the formula (I).

The ring shown below can be tetrahydronaphthalene, indan, indoline, tetrahydroquinoline, or tetrahydroisoquinoline.

R¹¹, R¹², and R¹⁶ in the formula (II) can be the same or different two or more substituents attached to the rings to which R¹¹, R¹², and R¹⁶ are attached.

R²¹, R²², and R²⁶ in the formula (III) can be the same or different two or more substituents attached to the rings to which R²¹, R²², and R²⁶ are attached.

The compound of the present invention of the formula (II) preferably is the following compound.

(1) A diazepine derivative having the formula (II) or a pharmacologically acceptable salt thereof, wherein R¹¹ is hydrogen, a C₁₋₈ alkyl group, a C₂₋₈ alkenyl group, a C₁₋₈ alkyl group having one to three halogen atoms, a halogen atom, hydroxyl, amino, a C₁₋₈ alkylamino group, a C₂₋₈ dialkylamino group, or a C₂₋₈ acylamino group.

(2) A diazepine derivative having the formula (II), a pharmacologically acceptable salt thereof or (1), wherein R¹² is hydrogen, a C₁₋₈ alkyl group, a C₁₋₈ alkoxy group, a C₁₋₈ alkyl group having one to three halogen atoms, a C₁₋₈ alkoxy group having one to three halogen atoms, a halogen atom, hydroxyl, nitro, cyano, amino, a C₁₋₈ alkylamino group, a C₂₋₈ dialkylamino group, a C₂₋₈ acylamino group, or a C₂₋₈ acylamino group having one to three halogen atoms.

(3) A diazepine derivative having the formula (II), a pharmacologically acceptable salt thereof, (1), or (2), wherein R¹³ is hydrogen, a C₁₋₈ alkyl group, or a C₁₋₈ alkyl group having one to three halogen atoms.

(4) A diazepine derivative having the formula (II), a pharmacologically acceptable salt thereof, or one of (1) to (3), wherein each of R¹⁴ and R¹⁵ independently is hydrogen, a C₁₋₈ alkyl group, or a C₁₋₈ alkyl group having one to three halogen atoms.

(5) A diazepine derivative having the formula (II), a pharmacologically acceptable salt thereof, or one of (1) to (4), wherein R¹⁶ is hydrogen, a C₁₋₈ alkyl group, a C₂₋₈ alkenyl group, a C₁₋₈ alkoxy group, a C₁₋₈ alkyl group having one to three halogen atoms, a C₁₋₈ alkoxy group having one to three halogen atoms, a halogen atom, hydroxyl, nitro, cyano, amino, a C₁₋₈ alkylamino group, a C₂₋₈ dialkylamino group, or a heterocyclic group optionally having one or more substituent.

(6) A diazepine derivative having the formula (II), a pharmacologically acceptable salt thereof, or one of (1) to (4), wherein R¹⁶ is a heterocyclic group optionally having one or more substituents, said heterocyclic group being tetrazolyl, triazolyl, pyridyl, pyrazolyl, oxadiazolyl, isoxazolyl, pyrrolyl, pyrrolidinyl, imidazolyl, oxazolyl, or thiazolyl, and said substituents being selected from the group consisting of a C₁₋₈ alkyl group, a C₁₋₈ alkoxy group, a C₁₋₈ alkyl group having one to three halogen atoms, a C₁₋₈ alkoxy group having one to three halogen atoms, a halogen atom, hydroxyl, nitro, cyano, amino, a C₁₋₈ alkylamino group, and a C₂₋₈ dialkylamino group.

(7) A diazepine derivative having the formula (II), a pharmacologically acceptable salt thereof, or one of (1) to (4), wherein R¹⁶ is a heterocyclic group optionally having one or more substituents, said heterocyclic group being tetrazolyl, triazolyl, pyridyl, imidazolyl, oxazolyl, or thiazolyl, and said substituents being selected from the group consisting of a C₁₋₈ alkyl group, a C₁₋₈ alkoxy group, a C₁₋₈ alkyl group having one to three halogen atoms, a C₁₋₈ alkoxy group having one to three halogen atoms, a halogen atom, hydroxyl, cyano, and amino.

(8) A diazepine derivative having the formula (II), a pharmacologically acceptable salt thereof, or one of (1) to (7), wherein the ring shown below is tetrahydronaphthalene, indan, indoline, tetrahydroquinoline, or tetrahydroisoquinoline.

(9) A diazepine derivative having the formula (II), a pharmacologically acceptable salt thereof, or one of (1) to (8), wherein the ring shown below is benzene.

(10) A diazepine derivative having the formula (II), a pharmacologically acceptable salt thereof, or one of (1) to (9), wherein each of each of Z¹ and Z² is O.

The compound of the present invention of the formula (III) preferably is the following compound.

(11) A diazepine derivative having the formula (III) or a pharmacologically acceptable salt thereof, wherein R²¹ is hydrogen, a C₁₋₈ alkyl group, a C₂₋₈ alkenyl group, a C₁₋₈ alkyl group having one to three halogen atoms, a halogen atom, hydroxyl, amino, a C₁₋₈ alkylamino group, a C₂₋₈ dialkylamino group, or a C₂₋₈ acylamino group.

(12) A diazepine derivative having the formula (II), a pharmacologically acceptable salt thereof or (11), wherein R²² is hydrogen, a C₁₋₈ alkyl group, a C₁₋₈ alkoxy group, a C₁₋₈ alkyl group having one to three halogen atoms, a C₁₋₈ alkoxy group having one to three halogen atoms, a halogen atom, hydroxyl, nitro, cyano, amino, a C₁₋₈ alkylamino group, a C₂₋₈ dialkylamino group, a C₂₋₈ acylamino group, or a C₂₋₈ acylamino group having one to three halogen atoms.

(13) A diazepine derivative having the formula (III), a pharmacologically acceptable salt thereof, (11), or (12), wherein R²³ is hydrogen, a C₁₋₈ alkyl group, or a C₁₋₈ alkyl group having one to three halogen atoms.

(14) A diazepine derivative having the formula (III), a pharmacologically acceptable salt thereof, or one of (11) to (13), wherein each of R²⁴ and R²⁵ independently is hydrogen, a C₁₋₈ alkyl group, or a C₁₋₈ alkyl group having one to three halogen atoms.

(15) A diazepine derivative having the formula (III), a pharmacologically acceptable salt thereof, or one of (11) to (14), wherein R²⁶ is hydrogen, a C₁₋₈ alkyl group, a C₂₋₈ alkenyl group, a C₁₋₈ alkoxy group, a C₁₋₈ alkyl group having one to three halogen atoms, a C₁₋₈ alkoxy group having one to three halogen atoms, a halogen atom, hydroxyl, nitro, cyano, amino, a C₁₋₈ alkylamino group, a O₂₋₈ dialkylamino group, or a heterocyclic group optionally having one or more substituent.

(16) A diazepine derivative having the formula (III), a pharmacologically acceptable salt thereof, or one of (11) to (14), wherein R²⁶ is a heterocyclic group optionally having one or more substituents, said heterocyclic group being tetrazolyl, triazolyl, pyridyl, pyrazolyl, oxadiazolyl, isoxazolyl, pyrrolyl, pyrrolidinyl, imidazolyl, oxazolyl, or thiazolyl, and said substituents being selected from the group consisting of a C₁₋₈ alkyl group, a C₁₋₈ alkoxy group, a C₁₋₈ alkyl group having one to three halogen atoms, a C₁₋₈ alkoxy group having one to three halogen atoms, a halogen atom, hydroxyl, nitro, cyano, amino, a C₁₋₈ alkylamino group, and a C₂₋₈ dialkylamino group.

(17) A diazepine derivative having the formula (III), a pharmacologically acceptable salt thereof, or one of (11) to (14), wherein R²⁶ is a heterocyclic group optionally having one or more substituents, said heterocyclic group being tetrazolyl, triazolyl, pyridyl, imidazolyl, oxazolyl, or thiazolyl, and said substituents being selected from the group consisting of a C₁₋₈ alkyl group, a C₁₋₈ alkoxy group, a C₁₋₈ alkyl group having one to three halogen atoms, a C₁₋₈ alkoxy group having one to three halogen atoms, a halogen atom, hydroxyl, cyano, and amino.

The pharmacologically acceptable salts of the compound represented by the formula (I), (II), or (III) include a hydrochloride salt and an alkali metal (e.g., sodium, potassium, lithium) salt.

The compound of the present invention can be a geometrical isomer or an optical isomer such as an optically active substance and racemic modification, each of which is included within the scope of the invention.

R³ in the formula (I), R¹³ in the formula (II), and R²³ in the formula (III) can be a C₂₋₈ acyl group such as acetyl.

R⁶ in the formula (I), R¹⁶ in the formula (II), and R²⁶ in the formula (III) can be a C₃₋₈ alkoxycarbonylamino group such as tert-butoxycarbonylamino.

The rings shown below in the formulas (I) and (II) can be 2,3-dihydrobenzo[1,4]dioxin.

The schemes for synthesis of the compound of the invention represented by the formula (III) are shown below.

In the above-illustrated formula, R²¹, R²², R²³, R²⁴, R²⁵, R²⁶, and p are defined above.

The compound of the invention represented by the formula (III) can be obtained by subjecting the compound represented by the formula (a) and the compound represented by the formula (b) to a ring-closing reaction in the presence of a solvent such as THF.

In the above-illustrated formula, R is a lower alkyl group, and R²¹, R²², R²³, R²⁴, R²⁵, R²⁶, and p are defined above.

The compound represented by the formula (e) can be obtained by reacting the compound represented by the formula (c) with the compound represented by the formula (d) in the presence of a solvent such as chloroform. The compound of the invention represented by the formula (III) can be obtained by subjecting the obtained compound represented by the formula (e) to a ring-closing reaction in the presence of sodium hydride in a solvent such as THF.

In the above-illustrated formula, R is a lower alkyl group, and R²¹, R²², R²⁴, R²⁵, R²⁶, and p are defined above.

The compound represented by the formula (h) can be obtained by reacting the compound represented by the formula (f) with the compound represented by the formula (g) in the presence of a solvent such as chloroform. The compound represented by the formula (I) can be obtained by subjecting the obtained compound represented by the formula (h) to a reductive reaction in the presence of a Pb catalyst in a solvent such as ethanol. The compound of the invention represented by the formula (j) can be obtained by subjecting the obtained compound represented by the formula (i) to a ring-closing reaction in the presence of a sodium alkoxide in a solvent such as ethanol.

In the above-illustrated formulas, R⁰ is a lower alkyl group, and R²¹, R²², R²³, R²⁴, R²⁵, and p are defined above.

The tetrazole compound represented by the formula (l) can be obtained by reacting the compound represented by the formula (k) with an azide compound such as tri-n-butyltin azide or sodium azide by the formula (g) in the presence of a solvent such as toluene or DMF.

The metal salt represented by the formula (m) can be obtained by reacting the tetrazole compound represented by the formula (l) with an inorganic salt such as sodium hydrogencarbonate and potassium hydrogencarbonate in the presence of a solvent such as water or ethanol.

The compound represented by the formula (O) or the formula (p) can be obtained by reacting the metal salt represented by the formula (m) with an alkyl iodide in the presence of a solvent such as water or ethanol.

The compound of the present invention represented by the formulas (I) and (II) can also be prepared by referring to the above-mentioned synthesis methods, the below described Examples, the patent documents described above, and the other known documents.

Examples of the obtained compounds of the present invention are shown below.

In the above-illustrated formula, A-B-D-E, R²³, R²⁴/R²⁵, and R²⁶ are shown in Tables 1 to 3.

TABLE 1 A-B-D-E R²³ R²⁴/R²⁵ R²⁶ CH₂—CH₂—CH₂—CH₂ H H/H 3-CN CH₂—CH₂—CH₂—CH₂ H H/H 3-OH CH₂—CH₂—CH₂—CH₂ H H/H 3-CO₂H CH₂—CH₂—CH₂—CH₂ H H/H 3-CONH₂ C(CH₃)₂—CH₂—CH₂—CH₂ H H/H 3,4-OCH₃ CH₂—C(CH₃)₂—CH₂—CH₂ CH₃ H/H 3,4-OCH₃ CH₂—CH₂—C(CH₃)₂—CH₂ C₂H₅ H/H 3-OH,4-F CH₂—CH₂—CH₂—CH₂ H H/H 3-NH₂ NH—CH₂—CH₂—CH₂ H H/H 3-NHCH₃ N(CH₃)—CH₂—CH₂—CH₂ H H/H 3-CF₃ O—CH₂—CH₂—O H H/H 3-NHCH₂CF₃ O—CH₂—CH₂—O CH₃ H/H 2-OH,3-OH C(CH₃)₂—CH₂—CH₂—C(CH₃)₂ C₂H₅ H/H 3,4,5-CH₃

TABLE 2 A-B-D-E R²³ R²⁴/R²⁵ R²⁶ CH₂—CH₂—CH₂—CH₂ H CH₃/H 4-OH CH₂—CH₂—CH₂—CH₂ H CH₃/CH₃ 4-NH₂ CH₂—CH₂—CH₂—CH₂ H propyl/H 4-NO₂ C(CH₃)₂—CH₂—CH₂—CH₂ H H/H 4-CN CH₂—C(CH₃)₂—CH₂—CH₂ CH₃ CF₃/H 4-phenyl CH₂—CH₂—C(CH₃)₂—CH₂ C₂H₅ H/H 4-CH₂OH CH₂—CH₂—CH₂—CH₂ H H/H 3-CH₂OH NH—CH₂—CH₂—CH₂ H H/H 3-COCH₃ N(CH₃)—CH₂—CH₂—CH₂ H H/H 3,5-OCH₃ O—CH₂—CH₂—O H H/H 3-OH,4-NH₂ O—CH₂—CH₂—O CH₃ H/H 3-CH₂NH₂ C(CH₃)₂—CH₂—CH₂—C(CH₃)₂ C₂H₅ H/H 3-SO₂CH₃ CH₂—CH₂—CH₂—CH₂ H CH₃/H 3-isopropyl CH₂—CH₂—CH₂—CH₂ H CH₃/H 3-N(CH₃)₂

TABLE 3 A-B-D-E R²³ R²⁴/R²⁵ R²⁶ CH₂—CH₂—CH₂—CH₂ H CH₃/H 4-COCH₃ C(CH₃)₂—CH₂—CH₂—CH₂ H propyl/H 3,4-NH₂ CH₂—C(CH₃)₂—CH₂—CH₂ H H/H NHCH₃ CH₂—CH₂—C(CH₃)₂—CH₂ C₂H₅ H/H 3-NHCH₂CF₃ CH₂—CH₂—CH₂—CH₂ H H/H 3-NHCOCH₃ NH—CH₂—CH₂—CH₂ H H/H 3-SO₂CH₃ N(CH₃)—CH₂—CH₂—CH₂ H H/H 4-CH₃ O—CH₂—CH₂—O H H/H 4-isopropyl O—CH₂—CH₂—O CH₃ H/H 3-phenyl C(CH₃)₂—CH₂—CH₂—C(CH₃)₂ C₂H₅ H/H 3-F,4-OH CH₂—CH₂—CH₂—CH₂ COCH₃ H/H 3-F,4-OCH₃ CH₂—CH₂—CH₂—CH₂ H CH₃/H 4-NHC₂H₅

In the above-illustrated formula, A-B-D-E, R²⁴/R²⁵, R²⁶, and R²⁷ are shown in Tables 4 to 6.

TABLE 4 A-B-D-E R²⁴/R²⁵ * R²⁶ R²⁷ CH₂—CH₂—CH₂—CH₂ H/H 3 1H-tetrazol-5-yl H C(CH₃)₂—CH₂—CH₂—CH₂ H/H 3 1H-tetrazol-5-yl H C(CH₃)₂—CH₂—CH₂—CH₂ H/H 3 1H-tetrazol-1-yl 4-F C(CH₃)₂CH₂CH₂C(CH₃)₂ H/H 3 2-methyl-2H-tetrazol- 3-F 5-yl CH₂—CH₂—C(CH₃)₂—CH₂ H/H 3 1,2,3-triazol-5-yl 2-F CH₂—CH₂—CH₂—CH₂ H/H 3 1,2,4-triazol-3-yl H NH—CH₂—CH₂—CH₂ H/H 3 5-trifluoromethyl- H 1,2,4-triazol-3-yl N(CH₃)—CH₂—CH₂—CH₂ H/H 4 1H-imidazol-1-yl H O—CH₂—CH₂-O H/H 4 1H-imidazol-2-yl H O—CH₂—CH₂-O H/H 3 5-cyano-1H-1,2,3- H triazol-4-yl C(CH₃)₂CH₂CH₂C(CH₃)₂ H/H 3 1-methyl-1H-tetrazol- H 5-yl CH₂—CH₂—CH₂—CH₂ CH₃/H 3 pyrazol-3-yl 4-OH CH₂—CH₂—CH₂—CH₂ CH₃/CH₃ 3 pyrazol-4-yl H (Remark) *: The position of R²⁶

TABLE 5 A-B-D-E R²⁴/R²⁵ * R²⁶ R²⁷ C(CH₃)₂—CH₂—CH₂—CH₂ H/H 3 5-oxo-1,2,4- 4-NH2 oxadiazol-3-yl CH₂—C(CH₃)₂—CH₂—CH₂ CF₃/H 3 1,2,4-oxadiazol-3-yl H CH₂CH₂—C(CH₃)₂—CH₂ H/H 3 1,3,4-oxadiazol-2-yl 4-F CH₂—CH₂—CH₂—CH₂ H/H 4 pyrrole-1-yl 3-F NH-CH₂—CH₂—CH₂ H/H 4 pyrrolidin-2-yl H N(CH₃)—CH₂—CH₂—CH₂ H/H 2 1,3-oxazol-5-yl H O—CH₂—CH₂—O H/H 3 1,3-thiazol-5-yl H O—CH₂—CH₂—O H/H 3 5-trifluoromethyl-1H- H imidazol-2-yl C(CH₃)₂CH₂CH₂C(CH₃)₂ H/H 3 5-chloro-1H-imidazol- 4-OH 2-yl (Remark) *: The position of R²⁶

TABLE 6 A-B-D-E R²⁴/R²⁵ * R²⁶ R²⁷ CH₂—CH₂—CH₂—CH₂ CH₃/H 4 5-methyl-1H- 4-NH₂ imidazol-2-yl CH₂—CH₂—CH₂—CH₂ CH₃/H 4 5-amino-1H- 3-F imidazol-2-yl CH₂—CH₂—CH₂—CH₂ CH₃/H 3 2-ethyl-2H- H tetrazol-5-yl C(CH₃)₂—CH₂—CH₂—CH₂ propyl/H 3 2-(2,2,2- 2,6-F trifluoroethyl)-2H- tetrazol-5-yl CH₂—C(CH₃)₂—CH₂—CH₂ H/H 3 1,3-oxazol-2-yl H CH₂—CH₂—C(CH₃)₂—CH₂ H/H 3 1,3-thiazol-2-yl H CH₂—CH₂—CH₂—CH₂ H/H 4 3,5-dimethyl- H isoxazol-4-yl NH—CH₂—CH₂—NH H/H 3 3-methyl-1,2,4- H oxadiazol-5-yl (Remark) *: The position of R²⁶

In the above-illustrated formula, A-B-D-E, R²⁴/R²⁵, and T⁰ are shown in Tables 7 to 9.

TABLE 7 A-B-D-E R²⁴/R²⁵ T⁰ CH₂—CH₂—CH₂—CH₂ H/H pyrimidin-2-yl C(CH₃)₂—CH₂—CH₂—CH₂ H/H pyrimidin-5-yl CH₂—C(CH₃)₂—CH₂—CH₂ H/H pyridin-2-yl CH₂—CH₂—C(CH₃)₂—CH₂ H/H pyridin-3-yl CH₂—CH₂—CH₂—CH₂ H/H pyridin-4-yl NH—CH₂—CH₂—CH₂ CH₃/H thiophen-2-yl N(CH₃)—CH₂—CH₂—CH₂ H/H thiophen-3-yl O—CH₂—CH₂—O H/H thiophen-3-yl O—CH₂—CH₂—O H/H 5-hydroxypyridin-3-yl C(CH₃)₂—CH₂—CH₂—C(CH₃)₂ H/H 5-methoxypyridin-3-yl CH₂—CH₂—CH₂—CH₂ F/H 5-aminopyridin-3-yl CH₂—CH₂—CH₂—CH₂ CH₃/CH₃ 5-chloropyridin-3-yl CH₂—CH₂—CH₂—CH₂ Propyl/H 6-chloropyridin-3-yl

TABLE 8 A-B-D-E R²⁴/R²⁵ T⁰ CH₂—CH₂—CH₂—CH₂ Propyl/H 6-chloropyridin-3-yl CH₂—CH₂—CH₂—CH₂ H/H 1H-indazol-6-yl C(CH₃)₂—CH₂—CH₂—CH₂ H/H 1H-indazol-5-yl CH₂—C(CH₃)₂—CH₂—CH₂ H/H 1H-indazol-4-yl CH₂—CH₂—C(CH₃)₂—CH₂ H/H 1H-benzotriazol-6-yl C(CH₃)₂—CH₂—CH₂—CH₂ H/H 1H-benzotriazol-4-yl CH₂—CH₂—CH₂—CH₂ H/H 1H-benzimidazol-6-yl CH₂—C(CH₃)₂—CH₂—CH₂ H/H 1H-indazol-4-yl CH₂—CH₂—C(CH₃)₂—CH₂ H/H 1H-indol-6-yl C(CH₃)₂—CH₂—CH₂—CH₂ H/H 1H-indol-5-yl C(CH₃)₂—CH₂—CH₂—CH₂ H/H 1H-indo1-4-yl CH₂—C(CH₃)₂—CH₂—CH₂ H/H benzisoxazol-6-yl C(CH₃)₂—CH₂—CH₂—CH₂ H/H 1H-benzimidazol-5-yl

TABLE 9 A-B-D-E R²⁴/R²⁵ T⁰ C(CH₃)₂—CH₂—CH₂—CH₂ H/H 1H-benzimidazol-6-yl CH₂—C(CH₃)₂—CH₂—CH₂ H/H 2-trifluoromethyl-1H- benzimidazol-5-yl CH₂—CH₂—CH₂—CH₂ H/H quinolin-5-yl C(CH₃)₂—CH₂—CH₂—CH₂ H/H quinolin-8-yl

In the above-illustrated formula, A-B-D, R²³, R²⁴/R²⁵, and R²⁶ are shown in Tables 10 to 12.

TABLE 10 A-B-D R²³ R²⁴/R²⁵ R²⁶ CH₂—CH₂—CH₂ H H/H 3-CN CH₂—CH₂—CH₂ H H/H 3-OH CH₂—CH₂—CH₂ H H/H 3-CO₂H CH₂—CH₂—CH₂ H H/H 3-CONH₂ O—CH₂—O H H/H 3,4-OCH₃ O—CH₂—O CH₃ H/H 3,4-OCH₃ O—CH₂—O C₂H₅ H/H 3-OH,4-F O—CH₂—O H H/H 3-NH₂ CH₂—CH₂—CH₂ H H/H 3-NHCH₃ CH₂—CH₂—CH₂ H H/H 3-CF₃ CH₂—CH₂—CH₂ H H/H 3-NHCH₂CF₃ CH₂—CH₂—CH₂ CH₃ H/H 2-OH,3-0H O—CH₂—O C₂H₅ H/H 3,4,5-CH₃

TABLE 11 A-B-D R²³ R²⁴/R²⁵ R²⁶ O—CH₂—O H CH₃/H 4-OH O—CH₂—O H CH₃/CH₃ 4-NH₂ O—CH₂—O H propyl/H 4-NO₂ CH₂—CH₂—CH₂ H H/H 4-CN CH₂—CH₂—CH₂ CH₃ CF₃/H 4-phenyl CH₂—CH₂—CH₂ C₂H₅ H/H 4-CH₂OH O—CH₂—O H H/H 3-CH₂OH CH₂—CH₂—CH₂ H H/H 3-COCH₃ CH₂—CH₂—CH₂ H H/H 3,5-OCH₃ CH₂—CH₂—CH₂ H H/H 3-OH,4-NH₂ O—CH₂—O CH₃ H/H 3-CH₂NH₂ CH₂—CH₂—CH₂ C₂H₅ H/H 3-SO₂CH₃ CH₂—CH₂—CH₂ H CH₃/H 3-isopropyl CH₂—CH₂—CH₂ H CH₃/H 3-N(CH₃)₂ O—CH₂—O H CH₃/H 4-COCH₃ CH₂—CH₂—CH₂ H propyl/H 3,4-NH₂

TABLE 12 A-B-D R²³ R²⁴/R²⁵ R²⁶ CH₂—CH₂—CH₂ H H/H NHCH₃ CH₂—CH₂—CH₂ C₂H₅ H/H 3-NHCH₂CF₃ O—CH₂—O H H/H 3-NHCOCH₃ CH₂—CH₂—CH₂ H H/H 3-SO₂CH₃ CH₂—CH₂—CH₂ H H/H 4-CH₃ CH₂—CH₂—CH₂ H H/H 4-isopropyl O—CH₂—O CH₃ H/H 3-phenyl CH₂—CH₂—CH₂ C₂H₅ H/H 3-F,4-OH CH₂—CH₂—CH₂ COCH₃ H/H 3-F,4-OCH₃

In the above-illustrated formula, A-B-D, R²⁴/R²⁵, R²⁶, and R²⁷ are shown in Tables 13 to 15.

TABLE 13 A-B-D-E R²⁴/R²⁵ * R²⁶ R²⁷ CH₂—CH₂—CH₂ H/H 3 1H-tetrazol-5-yl H CH₂—CH₂—CH₂ H/H 4 1H-tetrazol-5-yl H CH₂—CH₂—CH₂ H/H 3 1H-tetrazol-1-yl 4-F CH₂—CH₂—CH₂ H/H 3 2-methyl-2H-tetrazol-5-yl H O—CH₂—O H/H 3 1,2,3-triazol-5-yl 2-F O—CH₂—O H/H 3 1,2,4-triazol-3-yl H O—CH₂—O H/H 3 5-trifluoromethyl-1,2,4- H triazol-3-yl O—CH₂—O H/H 4 1H-imidazol-1-yl H CH₂—CH₂—CH₂ H/H 4 1H-imidazol-2-yl H CH₂—CH₂—CH₂ H/H 3 5-cyano-1H-1,2,3-triazol-4-yl H CH₂—CH₂—CH₂ H/H 3 1-methyl-1H-tetrazol-5-yl H CH₂—CH₂—CH₂ CH₃/H 3 pyrazol-3-yl 4-OH (Remark) *: The position of R26

TABLE 14 A-B-D R²⁴/R²⁵ * R²⁶ R²⁷ O—CH₂—O CH₃/CH₃ 3 pyrazol-4-yl H O—CH₂—O H/H 3 5-oxo-1,2,4-oxadiazol-3-yl 4-NH₂ O—CH₂—O CF₃/H 3 1,2,4-oxadiazol-3-yl H CH₂—CH₂—CH₂ H/H 3 1,3,4-oxadiazol-2-yl 4-F CH₂—CH₂—CH₂ H/H 4 pyrrole-1-yl 3-F CH₂—CH₂—CH₂ H/H 4 pyrrolidin-2-yl H O—CH₂—O H/H 2 1,3-oxazol-5-yl H CH₂—CH₂—CH₂ H/H 3 1,3-thiazol-5-yl H CH₂—CH₂—CH₂ H/H 3 5-trifluoromethyl-1H- H imidazol-2-yl CH₂—CH₂—CH₂ H/H 3 5-chloro-1H-imidazol-2-yl 4-OH O—CH₂—O CH₃/H 4 5-methyl-1H-imidazol-2-yl 4-NH₂ CH₂—CH₂—CH₂ CH₃/H 4 5-amino-1H-imidazol-2-yl 3-F (Remark) *: The position of R²⁶

TABLE 15 A-B-D R²⁴/R²⁵ * R²⁶ R²⁷ CH₂—CH₂—CH₂ CH₃/H 3 2-ethyl-2H-tetrazol-5-yl H CH₂—CH₂—CH₂ pro- 3 2-(2,2,2-trifluoroethyl)-2H- 2,6-F pyl/H tetrazol-5-yl O—CH₂—O H/H 3 1,3-oxazol-2-yl H CH₂—CH₂—CH₂ H/H 3 1,3-thiazol-2-yl H CH₂—CH₂—CH₂ H/H 4 3,5-dimethylisoxazol-4-yl H CH₂—CH₂—CH₂ H/H 3 3-methyl-1,2,4-oxadiazol-5-yl H (Remark) *: The position of R²⁶

In the above-illustrated formula, A-B-D, R²⁴/R²⁵, and T⁰ are shown in Tables 16 to 18.

TABLE 16 A-B-D R²⁴/R²⁵ T⁰ CH₂—CH₂—CH₂ H/H pyrimidin-2-yl CH₂—CH₂—CH₂ H/H pyrimidin-5-yl CH₂—CH₂—CH₂ H/H pyridin-2-yl CH₂—CH₂—CH₂ H/H quinolin-2-yl CH₂—CH₂—CH₂ H/H quinolin-3-yl CH₂—CH₂—CH₂ H/H pyridin-3-yl O—CH₂—O H/H pyridin-4-yl O—CH₂—O CH₃/H thiophen-2-yl O—CH₂—O H/H thiophen-3-yl O—CH₂—O H/H thiophen-3-yl CH₂—CH₂—CH₂ H/H 5-hydroxypyridin-3-yl CH₂—CH₂—CH₂ H/H 5-methoxypyridin-3-yl NH—CH₂—CH₂ F/H 5-aminopyridin-3-yl

TABLE 17 A-B-D-E R²⁴/R²⁵ T⁰ CH₂—CH₂—CH₂ CH₃/CH₃ 5-chloropyridin-3-yl O—CH₂—O propyl/H 6-chloropyridin-3-yl O—CH₂—O propyl/H 6-chloropyridin-3-yl O—CH₂—O H/H 1H-indazol-6-yl O—CH₂—O H/H 1H-indazol-5-yl CH₂—CH₂—CH₂ H/H 1H-indazol-4-yl CH₂—CH₂—CH₂ H/H 1H-benzotriazol-6-yl CH₂—CH₂—CH₂ H/H 1H-benzotriazol-4-yl O—CH₂—O H/H 1H-benzimidazol-6-yl CH₂—CH₂—CH₂ H/H 1H-indazol-4-yl CH₂—CH₂—CH₂ H/H 1H-indol-6-yl

TABLE 18 A-B-D-E R²⁴/R²⁵ T⁰ NH—CH₂—CH₂ H/H 1H-indo1-5-yl O—CH₂—O H/H 1H-indol-4-yl CH₂—CH₂—CH₂ H/H benzisoxazol-6-yl CH₂—CH₂—CH₂ H/H 1H-benzimidazol-5-yl CH₂—CH₂—CH₂ H/H 1H-benzimidazol-6-yl O—CH₂—O H/H 2-trifluoromethyl-1H-benzimidazol-5-yl CH₂—CH₂—CH₂ H/H quinolin-5-yl CH₂—CH₂—CH₂ H/H quinolin-8-yl

The pharmacological effects of the present invention are described below.

P2X₄ antagonism of the compound of the present invention is measured as described below.

1321N1 cells stably expressing human P2X₄ receptors were adopted for calcium influx assay. P2X₄/1321N1 cells were plated in 96-well assay plate and cultured for 24 hours in an atmosphere of 5% CO₂ at 37° C. Fura-2 AM calcium indicator dissolved in an extracellular solution for calcium imaging was loaded onto cells for 45 minutes at room temperature. The fluorescence was detected by FLUOstar OPTIMA micro plate reader (BMG labtech). The cells were alternatively illuminated with two excitations wavelengths (340 nm and 380 nm) via xenon lamp and the emitted fluorescence was measured at 510 nm. The fluorescence changes after the treatment of 1 μM ATP were monitored and determined the fluorescence ratio (F₃₄₀/F₃₈₀) as the index of intracellular calcium change. Tested compounds were treated to cells 15 min before the addition of ATP and the inhibition activities of compounds were calculated by comparing the Ca²⁺ response with control in the absence of tested compound.

As is evident from the below-described results shown in Examples 19 and 20, the compound of the present invention shows excellent P2X₄ receptor antagonism.

Therefore, it is considered that the diazepine derivative represented by the formula (I), (II), (III), or its pharmacologically acceptable salt, which shows P2X₄ receptor antagonism, is effective as an agent for prevention or treatment of nociceptive, inflammatory, and neuropathic pains. In more detail, it is effective as a preventive or therapeutic agent for pains caused by various cancers, diabetic neuritis, viral diseases such as herpes, and osteoarthritis. The preventive or therapeutic agent of the present invention can also be used in combination with other agents such as opioid analgesic (e.g., morphine, fentanyl), sodium channel inhibitor (e.g., novocaine, lidocaine), or NSAIDs (e.g., aspirin, ibuprofen). The agent for pains caused by cancers can be used in combination with a carcinostatic such as a chemotherapic.

The compound of the present invention can be administered to human beings by ordinary administration methods such as oral administration or parenteral administration.

The compound can be granulated in ordinary manners for the preparation of pharmaceuticals. For instance, the compound can be processed to give pellets, granule, powder, capsule, suspension, injection, suppository, and the like.

Ordinary additives such as vehicles, disintegrators, binders, lubricants, dyes, and diluents are used for the preparation of these pharmaceuticals. As the vehicles, lactose, D-mannitol, crystalline cellulose, and glucose can be mentioned. Further, there can be mentioned starch and carboxymethylcellulose calcium (CMC-Ca) as the disintegrators, magnesium stearate and talc as the lubricants, and hydroxypropylcellulose (HPC), gelatin and polyvinylpirrolidone (PVP) as the binders. The preparation of an injection can be made using solvents, stabilizers, dissolution-aids, suspensions, emulsifiers, soothing agents, buffers, or preservatives.

The compound of the invention can be administered to an adult generally in an amount of approx. 0.01 mg to 100 mg a day by parenteral administration and 1 mg to 2,000 mg a day by oral administration. The dosage can be adjusted in consideration of age and conditions of the patient.

The present invention is further described by the following non-limiting examples.

EXAMPLES Example 1 5-(3-Cyanophenyl)-8,9,10,11-tetrahydronaphtho[2,1-b][1,4]diazepine-2,4(3H,5H)-dione (1) 3-(1-Nitro-5,6,7,8-tetrahydronaphthalen-2-ylamino)benzonitrile

An anhydrous toluene (30 mL) suspension of 1-nitro-5,6,7,8-tetrahydronaphthalen-2-yl triflate (1.95 g, 6.00 mmol), 3-aminobenzonitrile (1.06 g, 9.00 mmol), potassium carbonate (830 mg, 6.00 mmol), tetrakis(triphenylphosphine)palladium (346 mg, 0.30 mmol), and triphenylphosphine (158 mg, 0.60 mmol) was stirred at 110° C. for 18 hours. The reaction mixture was cooled on standing, and filtered. The filtrate was diluted with ethyl acetate. The obtained organic solution was washed with purified water, and dried over anhydrous sodium sulfate. The solvent was removed by evaporation under reduced pressure. The residue was purified by silica gel column chromatography (chloroform) to give the titled compound as orange powder (1.515 g, yield 86%).

¹H NMR (CDCl₃, 400 MHz) δ: 1.7-1.9 (4H, m), 2.7-2.8 (4H, m), 6.90 (1H, br s), 7.1-7.4 (6H, m)

(2) 3-(1-Amino-5,6,7,8-tetrahydronaphthalen-2-ylamino)benzonitrile

To a methanol (10 mL) and anhydrous tetrahydrofuran (30 mL) solution of 3-(1-nitro-5,6,7,8-tetrahydronaphthalen-2-ylamino)benzonitrile (1.52 g, 5.17 mmol was added platinum oxide (50 mg), and the mixture was hydrogenated for 29 hours at room temperature under atmospheric pressure. After removal of the catalyst by filtration, the solvent was removed by evaporation under reduced pressure. The residue was purified by silica gel column chromatography (chloroform) to give the titled compound as yellow powder (747 mg, yield 55%).

¹H NMR (CDCl₃, 400 MHz) δ: 1.7-1.9 (4H, m), 2.50 (2H, t, J=6 Hz), 2.76 (2H, t, J=6 Hz), 3.77 (2H, br s), 5.26 (1H, br s), 6.54 (1H, d, J=8 Hz), 6.8-6.9 (3H, m), 7.02 (1H, d, J=7 Hz), 7.23 (1H, t, J=8 Hz)

(3) 5-(3-Cyanophenyl)-8,9,10,11-tetrahydronaphtho[2,1-b][1,4]diazepine-2,4(3H,5H)-dione

To an anhydrous tetrahydrofuran (30 mL) solution of 3-(1-amino-5,6,7,8-tetrahydronaphthalen-2-ylamino)benzonitrile (747 mg, 2.84 mmol) was added an anhydrous tetrahydrofuran (5 mL) solution of malonyl chloride (276 μL, 2.84 mmol) under cooling in ice-bath. The mixture was stirred for 30 minutes under cooling in ice-bath, and for 2 hours at room temperature. To the mixture was added purified water. The mixture was extracted with ethyl acetate, washed with purified water, and dried over anhydrous sodium sulfate. The solvent was removed by evaporation under reduced pressure. The residue was purified by silica gel chromatography (hexane/ethyl acetate=1/1) to give the titled compound as white powder (333 mg, yield 35%).

¹H NMR (CDCl₃, 400 MHz) δ: 1.7-2.1 (4H, m), 2.6-2.9 (4H, m), 3.49 (1H, d, =12 Hz), 3.54 (1H, d, J=12 Hz), 6.62 (1H, J=8 Hz), 6.88 (1H, d, J=8 Hz), 7.4-7.6 (4H, m), 7.67 (1H, br s)

Example 2 5-[3-(1H-Tetrazol-5-yl)phenyl]-8,9,10,11-tetrahydronaphtho[2,1-b][1,4]diazepine-2,4(3H,5H)-dione sodium salt (1) 5-[3-(1H-Tetrazol-5-yl)phenyl]-8,9,10,11-tetrahydronaphtho[2,1-b][1,4]diazepine-2,4(3H,5H)-dione

To an anhydrous DMF (5 mL) solution of 5-(3-cyanophenyl)-8,9,10,11-tetrahydronaphtho[2,1-b][1,4]diazepine-2,4(3H,5H)-dione (302 mg, 0.91 mmol) was added tri-n-butyltin azide (499 μL, 1.82 mmol). The mixture was stirred at 110° C. for 24 hours. The reaction mixture was cooled on standing, poured into saturated aqueous sodium hydrogen carbonate solution, and washed with ethyl acetate. After neutralization of the aqueous layer by addition of 1M hydrochloric acid, the layer was extracted with ethyl acetate, washed with purified water, and dried over anhydrous sodium sulfate. The solvent was removed by evaporation under reduced pressure. The residue was purified by chromatography (chloroform/methanol=95/5) to give the titled compound as slightly yellow powder (242 mg, yield 71%).

¹H NMR (CD₃OD, 400 MHz) δ: 1.7-2.0 (4H, m), 2.7-3.0 (4H, m), 3.28 (1H, d, J=12 Hz), 3.68 (1H, d, J=12 Hz), 6.76 (1H, d, J=8 Hz), 6.93 (1H, d, J=8 Hz), 7.44 (1H, d, J=8 Hz), 7.64 (1H, t, J=8 Hz), 7.88 (1H, s), 8.00 (1H, d, J=8 Hz)

(2) 5-[3-(1H-Tetrazol-5-yl)phenyl]-8,9,10,11-tetrahydronaphtho[2,1-b][1,4]diazepine-2,4(3H,5H)-dione sodium salt

To a methanol (2 mL) and purified water (1 mL) solution of 5-[3-(1H-tetrazol-5-yl)phenyl]-8,9,10,11-tetrahydronaphtho[2,1-b][1,4]diazepine-2,4(3H,5H)-dione (85 mg, 0.23 mmol) was added 1M aqueous sodium hydrogen carbonate solution (227 μL). The mixture was stirred at room temperature for 25 minutes. After concentrating the mixture under reduced pressure, the residue was washed with ether, and dried to solidify under reduced pressure to give the titled compound as pale yellow powder (86 mg, yield 96%).

¹H NMR (CD₃OD, 400 MHz) δ: 1.7-2.0 (4H, m), 2.7-3.0 (4H, m), 3.35 (2H, s), 6.79 (1H, d, J=9 Hz), 6.91 (1H, d, J=9 Hz), 7.31 (1H, d, J=8 Hz), 7.52 (1H, t, J=8 Hz), 7.82 (1H, s), 8.02 (1H, d, J=8 Hz)

IR(cm⁻¹, KBr): 3415, 2933, 1689, 1466, 1421, 1387, 1313, 984, 793, 760, 696.

Example 3 5-(3-Hydroxyphenyl)-8,9,10,11-tetrahydronaphtho[2,1-b][1,4]diazepine-2,4(3H,5H)-dione (1) N²-(3-Benzyloxyphenyl)-5,6,7,8-tetrahydronaphthalene-1,2-diamine

An anhydrous toluene (30 mL) suspension of 1-nitro-5,6,7,8-tetrahydronaphthalen-2-yl triflate (1.95 g, 6.00 mmol), 3-benzyloxyaniline (1.43 g, 7.20 mmol), potassium carbonate (0.83 g, 6.00 mmol), tetrakis(triphenylphosphine)palladium (0.35 g, 0.30 mmol), and triphenylphosphine (0.16 g, 0.60 mmol) was stirred at 110° C. for 16 hours. After cooling the mixture on standing, ethyl acetate and water were added to the mixture. Insolutile was removed by filtration. The organic layer was washed with saturated brine, and dried over anhydrous sodium sulfate. The solvent was removed by evaporation under reduced pressure. The residue was subjected to silica gel column chromatography (ethyl acetate/hexane=1/5) to give red oil (0.81 g).

The obtained crude 3-benzyloxy-N-(1-nitro-5,6,7,8-tetrahydronaphthalen-2-yl)aniline (0.81 g) was dissolved in tetrahydrofuran (10 mL)-ethanol (10 mL). To the solution was added concentrated hydrochloric acid (2 mL). To the mixture was added tin(II) chloride dihydrate (2.19 g, 9.72 mmol) over 5 minutes while stirring in ice-bath. The mixture was stirred at room temperature for 17 hours and at 50° C. for 4 hours. To the reaction mixture was added 2M aqueous sodium hydroxide solution (25 mL) while stirring in ice-bath. The mixture was extracted with ethyl acetate, washed with water and with saturated brine, and dried over anhydrous sodium sulfate. The solvent was removed by evaporation under reduced pressure to give red oil (0.81 g). The oil was purified by silica gel column chromatography (ethyl acetate/hexane=1/4) to give the titled compound as slightly yellow crystal (80 mg, yield 4%).

¹H NMR (CDCl₃, 400 MHz) δ: 1.7-1.9 (4H, m), 2.49 (2H, t, J=7 Hz), 2.74 (2H, t, J=7 Hz), 3.77 (2H, br s), 4.99 (2H, s), 5.07 (1H, br s), 6.2-6.3 (2H, m), 6.41 (1H, dd, J=2 Hz, 8 Hz), 6.51 (1H, d, J=8 Hz), 6.89 (1H, d, J=8 Hz), 7.09 (1H, t, J=8 Hz), 7.2-7.4 (5H, m).

(2) 5-(3-Benzyloxyphenyl)-8,9,10,11-tetrahydronaphtho[2,1-b][1,4]diazepine-2,4(3H,5H)-dione

To an anhydrous tetrahydrofuran (15 mL) solution of N²-(3-benzyloxyphenyl)-5,6,7,8-tetrahydronaphthalene-1,2-diamine (151 mg, 0.44 mmol) was added malonyl chloride (50 μL, 0.53 mmol) while stirring in ice-bath. The mixture was stirred at room temperature for 3 hours. To the mixture was added methanol (5 mL) while stirring in ice-bath. The mixture was stirred under cooling in ice-bath for 1 hour, and at room temperature for 1 hour. The solvent was removed by evaporation under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/hexane=1/1) to give the titled compound as yellow oil (58 mg, yield 32%).

¹H NMR (CDCl₃, 400 MHz) δ: 1.5-2.1 (4H, m), 2.6-2.9 (4H, m), 3.4-3.6 (2H, m), 4.99 (2H, s), 6.69 (1H, d, J=8 Hz), 6.8-7.0 (4H, m), 7.2-7.4 (6H, m).

(3) 5-(3-Hydroxyphenyl)-8,9,10,11-tetrahydronaphtho[2,1-b][1,4]diazepine-2,4(3H,5H)-dione

5-(3-Benzyloxyphenyl)-8,9,10,11-tetrahydronaphtho[2,1-b][1,4]diazepine-2,4(3H,5H)-dione (58 mg, 0.14 mmol) was dissolved in tetrahydrofuran (3 mL)-methanol (3 mL). To the solution was added 10% palladium-carbon (6 mg). The mixture was stirred under hydrogen atmosphere at room temperature for 6 hours. Insoluble was removed by filtration. The filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform/methanol=50/1) to give the titled compound as slightly yellow crystal (30 mg, yield 66%).

¹H NMR (DMSO-d₆, 400 MHz) δ: 1.6-1.9 (4H, m), 2.5-2.6 (1H, m), 2.6-2.8 (2H, m), 2.8-3.0 (1H, m), 3.01 (1H, d, J=12 Hz), 3.54 (1H, d, J=12 Hz), 6.5-6.6 (2H, m), 6.66 (1H, d, J=8 Hz), 6.70 (1H, dd, J=2 Hz, 8 Hz), 6.88 (1H, d, J=8 Hz), 7.19 (1H, t, J=8 Hz), 9.59 (1H, br s), 9.86 (1H, s).

Example 4 5-(3-Cyanophenyl)-5,8,9,10-tetrahydroindeno[5,4-b][1,4]diazepine-2,4(1H,3H)-dione (1) 4-Nitroindan-5-yl triflate

5-Indanol (13.4 g, 100 mmol) was dissolved in acetic acid (100 mL). To the solution was dropwise added fuming nitric acid (4.1 mL) over 10 minutes while stirring in ice-bath. The mixture was stirred under cooling in ice-bath for 30 minutes. The reaction mixture was poured into ice-cold water (270 mL), and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, and dried over anhydrous sodium sulfate. The solvent was removed by evaporation under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/hexane=1/10) to give yellow oil (12.5 g).

The obtained mixture of 4-nitro-5-indanol and 6-nitro-5-indanol (11.9 g, 66.4 mmol) was dissolved in dry dichloromethane (60 mL). To the solution was added triethylamine (10.2 mL, 73.0 mmol). To the solution was dropwise added trifluoromethanesulfonic anhydride (10.9 mL, 66.4 mmol) over 70 minutes while stirring in ice-bath. The mixture was stirred at room temperature for 3 hours. The solvent was removed by evaporation under reduced pressure. To the residue were added ice-cold water and 2M hydrochloric acid (4 mL). The mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, and dried over anhydrous sodium sulfate. The solvent was removed by evaporation under reduced pressure. The residue was purified by silica gel column chromatography (toluene/hexane=1/2-1/1) to give the titled compound as pale yellow crystal (7.0 g, yield 24%) and 6-nitroindan-5-yl triflate (12.0 g, yield 41%) as slightly yellow oil.

¹H NMR (CDCl₃, 400 MHz) δ: 2.1-2.3 (2H, m), 3.04 (2H, t, J=8 Hz), 3.21 (2H, t, =8 Hz), 7.22 (1H, d, J=8 Hz), 7.46 (1H, d, J=8 Hz).

(2) 3-(4-Nitroindan-5-yl)aminobenzonitrile

A dry toluene (50 mL) suspension of 4-nitroindan-5-yl triflate (3.11 g, 10.0 mmol), 3-aminobenzonitrile (1.77 g, 15.0 mmol), potassium carbonate (1.38 g, 10.0 mmol), tetrakis(triphenylphosphine)palladium (0.57 g, 0.50 mmol), and triphenylphosphine (0.26 g, 1.00 mmol) was refluxed for 66 hours. After cooling on standing, insoluble was removed by filtration. The filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/hexane=1/5) to give the titled compound as orange crystal (0.84 g, yield 30%).

¹H NMR (CDCl₃, 400 MHz) δ: 2.1-2.2 (2H, m), 2.93 (2H, t, J=8 Hz), 3.31 (2H, t, J=7 Hz), 7.17 (1H, d, J=8 Hz), 7.3-7.5 (5H, m), 8.64 (1H, s).

(3) 3-(4-Aminoindan-5-yl)aminobenzonitrile

3-(4-Nitroindan-5-ylamino)benzonitrile (0.84 g, 3.00 mmol) was dissolved in tetrahydrofuran (84 mL)-methanol (21 mL). To the solution was added water-containing 5% palladium-carbon (0.08 g). The mixture was stirred under hydrogen atmosphere at room temperature for 16 hours. Insoluble was removed by filtration. The filtrate was concentrated under reduced pressure to give the titled compound as yellowish brown crystal (0.75 g, yield 100%).

¹H NMR (CDCl₃, 400 MHz) δ: 2.1-2.2 (2H, m), 2.77 (2H, t, J=7 Hz), 2.94 (2H, t, J=8 Hz), 3.70 (2H, br s), 4.99 (2H, s), 5.28 (1H, br s), 6.67 (1H, d, J=8 Hz), 6.8-6.9 (3H, m), 7.02 (1H, d, J=8 Hz), 7.22 (1H, d, J=8 Hz).

(4) 5-(3-Cyanophenyl)-5,8,9,10-tetrahydroindeno[5,4-b][1,4]diazepine-2,4(1H,3H)-dione

To a dry tetrahydrofuran (75 mL) solution of 3-(4-aminoindan-5-ylamino)benzonitrile (0.75 g, 3.00 mmol) was added malonyl chloride (0.35 mL, 3.60 mmol) while stirring in ice-bath. The mixture was stirred under cooling in ice-bath for 1 hour and at room temperature for 1 hour. To the mixture was added methanol (5 mL) while stirring in ice-bath. The mixture was stirred under cooling in ice-bath for 1 hour and at room temperature for 1 hour. To the reaction mixture was added methanol (25 mL) while stirring in ice-bath. The mixture was stirred under cooling in ice-bath for 1 hour and at room temperature for 1 hour. The solvent was removed by evaporation under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/hexane=2/1-4/1) to slightly yellow crystal (0.40 g). The crystal was recrystallized from ethyl acetate to give the titled compound as white crystal (0.28 g, yield 29%).

Melting point 250-251° C.

¹H NMR (DMSO-d₆, 400 MHz) δ: 2.0-2.1 (2H, m), 2.7-3.0 (3H, m), 3.09 (1H, d, J=12 Hz), 3.1-3.3 (1H, m), 3.63 (1H, d, J=12 Hz), 6.63 (1H, d, J=8 Hz), 7.00 (1H, d, J=8 Hz), 7.45 (1H, d, J=8 Hz), 7.62 (1H, t, J=8 Hz), 7.7-7.8 (2H, m), 10.24 (1H, s).

Example 5 5-[3-(1H-Tetrazol-5-yl)phenyl]-5,8,9,10-tetrahydroindeno[5,4-b][1,4]diazepine-2,4(1H,3H)-dione sodium salt (1) 5-[3-(1H-Tetrazol-5-yl)phenyl]-5,8,9,10-tetrahydro-1H-indeno[5,4-b][1,4]diazepine-2,4(1H,3H)-dione

5-(3-Cyanophenyl)-5,8,9,10-tetrahydroindeno[5,4-b][1,4]diazepine-2,4(3H,5H)-dione (159 mg, 0.50 mmol) was mixed with tri-n-butyltin azide (332 mg, 1.00 mmol), toluene (8 mL) and dimethylformamide (2 mL). The mixture was refluxed for 24 hours. After cooling on standing, to the mixture was added 2M hydrochloric acid (2.5 mL), and the mixture was stirred at room temperature for 2 hours. The mixture was extracted with ethyl acetate, washed with saturated brine, and dried over anhydrous sodium sulfate. The solvent was removed by evaporation under reduced pressure. The residue was purified by silica gel column chromatography (chloroform/methanol=50/1) to give slightly yellow crystal. The crystal was recrystallized from acetone-hexane to give the titled compound as slightly yellow crystal (90 mg, yield 50%).

¹H NMR (CDCl₃, 400 MHz) δ: 2.1-2.4 (2H, m), 2.9-3.1 (3H, m), 3.2-3.3 (1H, m), 3.59 (1H, d, J=11 Hz), 3.66 (1H, d, J=11 Hz), 6.52 (1H, d, J=8 Hz), 6.67 (1H, s), 6.94 (1H, d, J=8 Hz), 7.12 (1H, t, J=8 Hz), 7.52 (1H, d, J=8 Hz), 7.83 (1H, d, J=8 Hz), 9.67 (1H, br s).

(2) 5-[3-(1H-Tetrazol-5-yl)phenyl]-5,8,9,10-tetrahydroindeno[5,4-b][1,4]diazepine-2,4(1H,3H)-dione sodium salt

5-[3-(1H-Tetrazol-5-yl)phenyl]-5,8,9,10-tetrahydroindeno[5,4-b][1,4]diazepine-2,4(1H,3H)-dione (90 mg, 0.25 mmol) was dissolved in ethanol (45 mL). To the solution was added a solution of sodium hydrogencarbonate (21 mg, 0.25 mmol) in water (4 mL). The solvent was removed by evaporation under reduced pressure to give the titled compound as a pale brown amorphous form (97 mg, yield 100%).

¹H NMR (DMSO-d₆, 400 MHz) δ: 2.0-2.1 (2H, m), 2.7-3.0 (3H, m), 3.09 (1H, d, J=12 Hz), 3.1-3.3 (1H, m), 3.64 (1H, d, J=12 Hz), 6.72 (1H, d, J=8 Hz), 6.98 (1H, d, J=8 Hz), 7.16 (1H, d, J=8 Hz), 7.44 (1H, t, J=8 Hz), 7.61 (1H, s), 7.91 (1H, d, J=7 Hz), 10.21 (1H, s).

Example 6 5-[3-(2-Methyl-2H-tetrazol-5-yl)phenyl]-5,8,9,10-tetrahydroindeno[5,4-b][1,4]diazepine-2,4(1H,3H)-dione and 5-[3-(1-methyl-1H-tetrazol-5-yl)phenyl]-5,8,9,10-tetrahydroindeno[5,4-b][1,4]diazepine-2,4(1H,3H)-dione

5-[3-(1H-Tetrazol-5-yl)phenyl]-5,8,9,10-tetrahydroindeno[5,4-b][1,4]diazepine-2,4(1H,3H)-dione sodium salt (46 mg, 0.12 mmol) was dissolved in dry dimethylsulfoxide (2 mL). To the solution was added methyl iodide (37 μL, 0.60 mmol). The mixture was stirred at room temperature for 72 hours. To the mixture was added water. The mixture was extracted with ethyl acetate, washed with saturated brine, and dried over anhydrous sodium sulfate. The solvent was removed by evaporation under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/hexane=2/1-3/1) to give 5-[3-(2-methyl-2H-tetrazol-5-yl)phenyl]-5,8,9,10-tetrahydroindeno[5,4-b][1,4]diazepine-2,4(1H,3H)-dione (17 mg, yield 38%) and 5-[3-(1-methyl-1H-tetrazol-5-yl)phenyl]-5,8,9,10-tetrahydroindeno[5,4-b][1,4]diazepine-2,4(1H,3H)-dione (5 mg, yield 11%).

¹H NMR (DMSO-d₆, 400 MHz)

5-[3-(2-Methyl-2H-tetrazol-5-yl)phenyl]-5,8,9,10-tetrahydroindeno[5,4-b][1,4]diazepine-2,4(1H,3H)-dione δ: 2.0-2.1 (2H, m), 2.7-3.0 (3H, m), 3.10 (1H, d, J=12 Hz), 3.1-3.3 (1H, m), 3.66 (1H, d, J=12 Hz), 4.41 (3H, s), 6.70 (1H, d, J=8 Hz), 7.00 (1H, d, J=8 Hz), 7.38 (1H, d, J=8 Hz), 7.63 (1H, t, J=8 Hz), 7.77 (1H, s), 8.00 (1H, d, J=7 Hz), 10.22 (1H, s).

5-[3-(1-Methyl-1H-tetrazol-5-yl)phenyl]-5,8,9,10-tetrahydroindeno[5,4-b][1,4]diazepine-2,4(1H,3H)-dione δ: 2.0-2.1 (2H, m), 2.7-3.0 (3H, m), 3.10 (1H, d, J=12 Hz), 3.1-3.3 (1H, m), 3.65 (1H, d, J=12 Hz), 4.16 (3H, s), 6.72 (1H, d, J=8 Hz), 7.01 (1H, d, J=8 Hz), 7.39 (1H, d, J=8 Hz), 7.67 (1H, t, J=8 Hz), 7.73 (1H, s), 7.80 (1H, d, J=8 Hz), 10.23 (1H, s).

Example 7 5-(3-tert-Butoxycarbonylaminophenyl)-1,5,8,9,10,11-hexahydronaphtho[1,2-b][1,4]diazepine-2,4-dione (1) tert-Butyl 3-(1-nitro-5,6,7,8-tetrahydronaphthalen-2-ylamino)phenyl]carbamate

1-Nitro-5,6,7,8-tetrahydronaphthalen-2-yl triflate (2.00 g, 6.15 mmol) and tert-butyl(3-aminophenyl)carbamate (1.28 g, 6.15 mmol) were used in a process similar to Example 1 (1) to give the titled compound as red oil (1.51 g, yield 64%).

¹H NMR (CDCl₃, 400 MHz) δ: 1.51 (9H, s), 1.7-1.8 (4H, m), 2.7-2.8 (4H, m), 6.75 (1H, dd, J=2 Hz, 8 Hz), 6.89 (1H, dd, J=2 Hz, 8 Hz), 7.0-7.1 (2H, m), 7.1-7.2 (2H, m), 7.24 (1H, br s).

(2) tert-Butyl 3-(1-amino-5,6,7,8-tetrahydronaphthalen-2-ylamino)phenyl]carbamate

tert-Butyl 3-(1-nitro-5,6,7,8-tetrahydronaphthalen-2-ylamino)phenyl]carbamate (1.50 g, 3.91 mmol) and 10% palladium-carbon (0.15 g) were used in a process similar to Example 1(2) to give the titled compound as white crystal (0.78 g, yield 57%).

¹H NMR (CDCl₃, 400 MHz) δ: 1.49 (9H, s), 1.7-2.0 (4H, m), 2.49 (2H, t, J=6 Hz), 2.74 (2H, t, J=6 Hz), 3.80 (2H, br s), 5.08 (1H, br s), 6.3-6.4 (2H, m), 6.52 (1H, d, J=8 Hz), 6.89 (1H, d, J=8 Hz), 7.06 (1H, t, J=8 Hz).

(3) 5-(3-tert-Butoxycarbonylaminophenyl)-1,5,8,9,10,11-hexahydronaphtho[1,2-b][1,4]diazepine-2,4-dione

tert-Butyl 3-(1-amino-5,6,7,8-tetrahydronaphthalen-2-ylamino)phenyl]carbamate (353 mg, 1.0 mmol) was used in a process similar to Example 1(3) to give the titled compound as a yellow amorphous substance (220 mg, yield 52%).

¹H NMR (CDCl₃, 400 MHz) δ: 1.48 (9H, s), 1.7-2.1 (4H, m), 2.6-2.8 (4H, m), 3.4-3.5 (2H, m), 6.71 (1H, d, J=8 Hz), 6.7-6.9 (3H, m), 7.2-7.4 (3H, m), 8.21 (1H, br s).

Example 8 5-(3-Aminophenyl)-1,5,8,9,10,11-hexahydronaphtho[1,2-b][1,4]diazepine-2,4-dione hydrochloride

5-(3-tert-Butoxycarbonylaminophenyl)-1,5,8,9,10,11-hexahydronaphtho[1,2-b][1,4]diazepine-2,4-dione (180 mg, 0.43 mmol) obtained in Example 7(3) was suspended in dichloromethane (15 mL). To the suspension was dropwise added a mixed solution of trifluoroacetic acid (3 mL)dichloromethane (3 mL) while stirring in ice-bath. The mixture was stirred under cooling in ice-bath for 1 hour and at room temperature for 1 hour. To the mixture were added potassium carbonate and a small amount of water.

The mixture was extracted with dichloromethane, and dried over anhydrous sodium sulfate. The solvent was removed by evaporation. The residue was purified by NH silica gel column chromatography (chloroform) to give 5-(3-aminophenyl)-1,5,8,9,10,11-hexahydronaphtho[1,2-b][1,4]diazepine-2,4-dione as a colorless amorphous form (73 mg, 0.23 mmol).

The obtained amorphous form was dissolved in ethyl acetate (1.5 mL)-methanol (0.5 mL). To the solution was added 4M hydrogen chloride-ethyl acetate (0.056 mL) while stirring in ice-bath. The mixture was stirred overnight at room temperature. Precipitates were obtained by filtration, washed with ethyl acetate, and with hexane to give the titled compound as a yellow amorphous form (67 mg, yield 23%).

¹H NMR (CD₃OD, 400 MHz) δ: 1.7-2.1 (4H, m), 2.7-2.9 (4H, m), 3.25 (1H, d, J=12 Hz), 3.66 (1H, d, J=12 Hz), 6.70 (1H, d, J=8 Hz), 6.93 (1H, d, J=9 Hz), 7.22 (1H, d, J=8 Hz), 7.3-7.4 (2H, m), 7.55 (1H, t, J=8 Hz).

Example 9 5-[3-(2-Methyl-2H-tetrazol-5-yl)phenyl]-1,5,8,9,10,11-hexahydronaphtho[1,2-b][1,4]diazepine-2,4-dione

5-[3-(1-Methyl-1H-tetrazol-5-yl)phenyl]-1,5,8,9,10,11-hexahydronaphtho[1,2-b][1,4]diazepine-2,4-dione

5-[3-(1H-Tetrazol-5-yl)phenyl]-1,5,8,9,10,11-hexahydronaphtho[1,2-b][1,4]diazepine-2,4-dione sodium salt (40 mg, 0.10 mmol) obtained in Example 2 was used in a process similar to Example 6 to give 5-[3-(2-methyl-2H-tetrazol-5-yl)phenyl]-1,5,8,9,10,11-hexahydronaphtho[1,2-b][1,4]diazepine-2,4-dione as slightly brown crystal (18 mg, yield 46%) and 5-[3-(1-methyl-1H-tetrazol-5-yl)phenyl]-1,5,8,9,10,11-hexahydronaphtho[1,2-b][1,4]diazepine-2,4-dione as slightly brown crystal (3 mg, yield 8%).

5-[3-(2-Methyl-2H-tetrazol-5-yl)phenyl]-1,5,8,9,10,11-hexahydronaphtho[1,2-b][1,4]diazepine-2,4-dione

¹H NMR (DMSO-d₆, 400 MHz) δ: 1.6-1.9 (4H, m), 2.5-2.8 (3H, m), 2.9-3.0 (1H, m), 3.07 (1H, d, J=12 Hz), 3.62 (1H, d, J=12 Hz), 4.41 (3H, s), 6.67 (1H, d, J=8 Hz), 6.89 (1H, d, J=8 Hz), 7.38 (1H, d, J=8 Hz), 7.63 (1H, t, J=8 Hz), 7.77 (1H, s), 8.00 (1H, d, J=7 Hz), 9.91 (1H, s).

5-[3-(1-Methyl-1H-tetrazol-5-yl)phenyl]-1,5,8,9,10,11-hexahydronaphtho[1,2-b][1,4]diazepine-2,4-dione

¹H NMR (DMSO-d₆, 400 MHz) δ: 1.6-1.9 (4H, m), 2.5-2.8 (3H, m), 2.9-3.0 (1H, m), 3.08 (1H, d, J=12 Hz), 3.61 (1H, d, J=12 Hz), 4.16 (3H, s), 6.69 (1H, d, J=8 Hz), 6.90 (1H, d, J=8 Hz), 7.39 (1H, d, J=8 Hz), 7.67 (1H, t, J=8 Hz), 7.72 (1H, s), 7.80 (1H, d, J=7 Hz), 9.91 (1H, s).

Example 10 5-(4-Aminophenyl)-1,5,8,9,10,11-hexahydronaphtho[1,2-b][1,4]diazepine-2,4-dione (1) tert-Butyl 4-(1-nitro-5,6,7,8-tetrahydronaphthalen-2-ylamino) phenylcarbamate

1-Nitro-5,6,7,8-tetrahydronaphthalen-2-yl triflate (3.25 g, 10 mmol) and tert-butyl (4-aminophenyl)carbamate (2.08 g, 10 mmol) were used in a process similar to Example 1(1) to give the titled compound as a red solid (1.88 g, yield 49%).

¹H NMR (CDCl₃, 400 MHz) δ: 1.54 (9H, s), 1.7-1.8 (4H, m), 2.6-2.9 (4H, m), 3.81 (2H, br s), 6.40 (1H, br s), 6.9-7.1 (4H, m), 7.21 (1H, s), 7.2-7.4 (2H, m).

(2) tert-Butyl 4-(1-amino-5,6,7,8-tetrahydronaphthalen-2-ylamino)phenylcarbamate

tert-Butyl 4-(1-nitro-5,6,7,8-tetrahydronaphthalen-2-ylamino)phenylcarbamate (1.87 g, 4.88 mmol) was used in a process similar to Example 1(2) to give the titled compound as orange crystal (1.42 g, yield 83%).

¹H NMR (CDCl₃, 400 MHz) δ: 1.50 (9H, s), 1.7-1.9 (4H, m), 2.4-2.9 (4H, m), 3.81 (2H, br s), 6.24 (1H, br s), 6.4-6.7 (3H, m), 6.8-6.9 (1H, m), 7.0-7.3 (2H, m).

(3) 5-(4-tert-Butoxycarbonylaminophenyl)-1,5,8,9,10,11-hexahydronaphtho[1,2-b][1,4]diazepine-2,4-dione

5-(4-tert-Butoxycarbonylaminophenyl)-1,5,8,9,10,11-hexahydronaphtho[1,2-b][1,4]diazepine-2,4-dione (1.42 g, 4.02 mmol) was used in a process similar to Example 1(3) to give the titled compound as a pale yellow amorphous form (0.38 g, yield 23%).

¹H NMR (CDCl₃, 400 MHz) δ: 1.51 (9H, s), 1.7-2.1 (4H, m), 2.5-2.8 (4H, m), 3.48 (2H, s), 6.53 (1H, bs), 6.69 (1H, d, J=8 Hz), 6.82 (1H, d, J=8 Hz), 7.1-7.2 (2H, m), 7.3-7.4 (2H, m), 7.52 (1H, br s).

(4) 5-(4-Aminophenyl)-1,5,8,9,10,11-hexahydronaphtho[1,2-b][1,4]diazepine-2,4-dione

5-(4-tert-Butoxycarbonylaminophenyl)-1,5,8,9,10,11-hexahydronaphtho[1,2-b][1,4]diazepine-2,4-dione (350 mg, 0.83 mmol) was used in a process similar to Example 8 to give the titled compound as white crystal (204 mg, yield 76%).

¹H NMR (CDCl₃, 400 MHz) δ: 1.7-2.1 (4H, m), 2.6-2.8 (4H, m), 3.4-3.5 (2H, m), 6.6-6.7 (2H, m), 6.74 (1H, d, J=8 Hz), 6.84 (1H, d, J=8 Hz), 6.9-7.0 (2H, m).

Example 11 5-(4-Methylaminophenyl)-1,5,8,9,10,11-hexahydronaphtho[1,2-b][1,4]diazepine-2,4-dione hydrochloride (1) N-[4-(2,4-Dioxo-1,2,3,4,8,9,10,11-octahydronaphtho[1,2-b][1,4]diazepine-5-yl)phenyl]-2-nitrobenzenesulfonamide

5-(4-Aminophenyl)-1,5,8,9,10,11-hexahydronaphtho[1,2-b][1,4]diazepine-2,4-dione (190 mg, 0.59 mmol) obtained in Example 10, o-nitrobenzenesulfonyl chloride (197 mg, 0.89 mmol), and dry pyridine (5 mL) were mixed. The mixture was stirred at 80° C. for 17 hours. Pyridine was removed by evaporation under reduced pressure. To the residue was added water. The mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with dilute hydrochloric acid, and dried over anhydrous sodium sulfate. The solvent was removed by evaporation under reduced pressure. The residue was purified by silica gel column chromatography (chloroform) to give the titled compound as pale yellow crystal (233 mg, yield 78%).

¹H NMR (CDCl₃, 400 MHz) δ: 1.7-2.1 (4H, m), 2.6-2.8 (4H, m), 3.4-3.5 (2H, m), 6.60 (1H, d, J=8 Hz), 6.83 (1H, d, J=8 Hz), 7.1-7.2 (2H, m), 7.2-7.3 (2H, m), 7.47 (1H, s), 7.62 (1H, dt, J=1 Hz, 8 Hz), 7.71 (1H, dt, J=1 Hz, 8 Hz), 7.80 (1H, s), 7.86 (1H, dd, J=1 Hz, 8 Hz), 7.91 (1H, dd, J=1 Hz, 8 Hz).

(2) N-[4-(2,4-Dioxo-1,2,3,4,8,9,10,11-octahydronaphtho[1,2-b][1,4]diazepine-5-yl)phenyl]-N-methyl-2-nitrobenzenesulfonamide

N-[4-(2,4-Dioxo-1,2,3,4,8,9,10,11-octahydronaphtho[1,2-b][1,4]diazepine-5-yl)phenyl]-2-nitrobenzenesulfonamide (150 mg, 0.3 mmol), methyl iodide (22 μL, 0.36 mmol), potassium carbonate (45 mg, 0.33 mmol), and dry dimethylformamide (3 mL) were mixed. The mixture was stirred at room temperature for 16 hours. The solvent was removed by evaporation under reduced pressure. To the residue was added water. The mixture was stirred at room temperature. Insoluble was obtained by filtration, washed with water, and air-dried overnight to give the titled compound as off-white crystal (112 mg, yield 73%).

¹H NMR (DMSO-d₆, 400 MHz) δ: 1.6-1.9 (4H, m), 2.6-2.8 (3H, m), 2.8-3.0 (1H, m), 3.04 (1H, d, J=12 Hz), 3.57 (1H, d, J=12 Hz), 6.62 (1H, d, J=8 Hz), 6.90 (1H, d, J=9 Hz), 7.16 (2H, d, J=9 Hz), 7.27 (2H, d, J=9 Hz), 7.72 (1H, dd, J=1 Hz, 8 Hz), 7.80 (1H, dt, J=1 Hz, 8 Hz), 7.91 (1H, dt, J=1 Hz, 8 Hz), 7.97 (1H, dd, J=1 Hz, 8 Hz), 9.90 (1H, s).

(3) 5-(4-Methylaminophenyl)-1,5,8,9,10,11-hexahydronaphtho[1,2-b][1,4]diazepine-2,4-dione hydrochloride

N-[4-(2,4-Dioxo-1,2,3,4,8,9,10,11-octahydronaphtho[1,2-b][1,4]diazepine-5-yl)phenyl]-N-methyl-2-nitrobenzenesulfonamide (50 mg, 0.096 mmol) was dissolved in dry dimethylformamide (2 mL). To the solution were added potassium carbonate (40 mg, 0.29 mmol), and then thiophenol (12 μL, 0.12 mmol). The mixture was stirred overnight at room temperature. To the reaction mixture was added cold water. The mixture was extracted with ethyl acetate, washed with saturated brine, and dried over anhydrous sodium sulfate. The solvent was removed by evaporation under reduced pressure. The residue was purified by silica gel column chromatography (chloroform) to give 5-(4-methylaminophenyl)-1,5,8,9,10,11-hexahydronaphtho[1,2-b][1,4]diazepine-2,4-dione as a colorless amorphous form (32 mg, 0.095 mmol).

The obtained amorphous form was dissolved in ethyl acetate. To the solution was added 4M hydrogen chloride-ethyl acetate (25 μL). The mixture was stirred at room temperature for 1 hour. Precipitates were collected by filtration, washed with ethyl acetate, and with hexane to give the titled compound as off-white crystal (22 mg, yield 61%).

¹H NMR (DMSO-d₆, 400 MHz) δ: 1.6-1.9 (4H, m), 2.5-2.8 (3H, m), 2.72 (3H, s), 2.8-3.0 (1H, m), 3.00 (1H, d, J=12 Hz), 3.50 (1H, d, J=12 Hz), 6.64 (1H, d, J=8 Hz), 6.6-6.8 (2H, m), 6.85 (1H, d, J=9 Hz), 6.93 (2H, d, J=8 Hz), 9.82 (1H, s).

Example 12 5-(2,3-Dihydrobenzo[1,4]dioxin-6-yl)-1,5,8,9,10,11-hexahydronaphtho[1,2-b][1,4]diazepine-2,4-dione (1) 6-(1-Nitro-5,6,7,8-tetrahydronaphthalen-2-ylamino)-2,3-dihydrobenzo[1,4]dioxin

1-Nitro-5,6,7,8-tetrahydronaphthalen-2-yl triflate (3.25 g, 10 mmol) and 6-amino-2,3-dihydrobenzo[1,4]dioxin (1.51 g, 10 mmol) were used in a process similar to Example 1(1) to give the titled compound as red oil (3.20 g, yield 98%).

¹H NMR (CDCl₃, 400 MHz) δ: 1.7-1.8 (4H, m), 2.70 (2H, t, J=5 Hz), 2.80 (2H, t, J=5 Hz), 4.2-4.3 (4H, m), 6.60 (1H, dd, J=2 Hz, 8 Hz), 6.67 (1H, d, J=2 Hz), 6.81 (1H, d, J=8 Hz), 6.97 (1H, d, J=9 Hz), 7.00 (1H, d, J=9 Hz), 7.17 (1H, br s).

(2) 6-(1-Amino-5,6,7,8-tetrahydronaphthalen-2-ylamino)-2,3-dihydrobenzo[1,4]dioxin

6-(1-Nitro-5,6,7,8-tetrahydronaphthalen-2-ylamino)-2,3-dihydrobenzo[1,4]dioxin (3.20 g, 9.81 mmol) were used in a process similar to Example 1(2) to give the titled compound as pale pink crystal (2.58 g, yield 89%).

¹H NMR (CDCl₃, 400 MHz) δ: 1.7-1.9 (4H, m), 2.4-2.8 (4H, m), 4.1-4.2 (4H, m), 6.1-6.3 (2H, m), 6.4-6.6 (1H, m), 6.70 (1H, d, J=9 Hz), 6.85 (1H, d, J=9 Hz).

(3) 5-(2,3-Dihydrobenzo[1,4]dioxin-6-yl)-1,5,8,9,10,11-hexahydronaphtho[1,2-b][1,4]diazepine-2,4-dione

6-(1-Amino-5,6,7,8-tetrahydronaphthalen-2-ylamino)-2,3-dihydrobenzo[1,4]dioxin (1.06 g, 3.58 mmol) were used in a process similar to Example 1(3) to give the titled compound as a pale brown amorphous form (0.49 g, yield 38%).

¹H NMR (CDCl₃, 400 MHz) δ: 1.7-2.1 (4H, m), 2.5-2.8 (4H, m), 3.47 (2H, s), 4.2-4.3 (4H, m), 6.66 (1H, dd, J=2 Hz, 8 Hz), 6.7-6.8 (2H, m), 6.8-6.9 (2H, m), 7.6-7.7 (1H, m).

Example 13 5-(4-Methoxyphenyl)-1,5,8,9,10,11-hexahydronaphtho[1,2-b][1,4]diazepine-2,4-dione (1) N²-(4-Methoxyphenylamino)-5,6,7,8-tetrahydronaphthalene-1,2-diamine

1-Nitro-5,6,7,8-tetrahydronaphthalen-2-yl triflate (3.25 g, 10 mmol) and p-anisidine (1.23 g, 10 mmol) were used in a process similar to Example 3(1) to give the titled compound as an orange amorphous form (0.82 g, yield 31%).

¹H NMR (CDCl₃, 400 MHz) δ: 1.7-1.9 (4H, m), 2.4-2.6 (2H, m), 2.7-2.8 (2H, m), 3.75 (3H, s), 3.78 (2H, br s), 4.86 (1H, br s), 6.51 (1H, d, J=8 Hz), 6.6-6.7 (2H, m), 6.7-6.8 (2H, m), 6.85 (1H, d, J=8 Hz).

(2) 5-(4-Methoxyphenyl)-1,5,8,9,10,11-hexahydronaphtho[1,2-b][1,4]diazepine-2,4-dione

N²-(4-Methoxyphenylamino)-5,6,7,8-tetrahydronaphthalene-1,2-diamine (725 mg, 2.7 mmol) was used in a process similar to Example 1(3) to give the titled compound as a pale yellow amorphous form (224 mg, yield 25%).

¹H NMR (CDCl₃, 400 MHz) δ: 1.7-2.1 (4H, m), 2.5-2.8 (4H, m), 3.49 (2H, s), 3.81 (3H, s), 6.72 (1H, d, J=8 Hz), 6.84 (1H, d, J=8 Hz), 6.8-7.0 (2H, m), 7.1-7.2 (2H, m), 7.44 (1H, br s).

Example 14 5-(4-Hydroxyphenyl)-1,5,8,9,10,11-hexahydronaphtho[1,2-b][1,4]diazepine-2,4-dione

5-(4-Methoxyphenyl)-1,5,8,9,10,11-hexahydronaphtho[1,2-b][1,4]diazepine-2,4-dione (200 mg, 0.59 mmol) obtained in Example 13 was dissolved in dry dichloromethane (5 mL) while stirring in ice-bath. To the solution was dropwise added 1M boron tribromidedichloromethane (1.2 mL). The mixture was stirred at room temperature for 16 hours and at 50° C. for 3 hours. The solvent was removed by evaporation under reduced pressure. To the residue was added cold water. The mixture was extracted with ethyl acetate, washed with saturated brine, and dried over anhydrous sodium sulfate. The solvent was removed by evaporation under reduced pressure. The residue was purified by silica gel column chromatography (chloroform/methanol=100/1) to give the titled compound as a white amorphous form (124 mg, yield 64%).

¹H NMR (DMSO-d₆, 400 MHz) δ: 1.6-1.9 (4H, m), 2.5-2.7 (3H, m), 2.8-3.0 (1H, m), 3.00 (1H, d, J=12 Hz), 3.50 (1H, d, J=12 Hz), 6.63 (1H, d, J=9 Hz), 6.7-6.8 (2H, m), 6.85 (1H, d, J=9 Hz), 6.9-7.0 (2H, m), 9.60 (1H, br s), 9.82 (1H, s).

Example 15 5-[4-(Isopropylcarbonylamino)phenyl]-1,5,8,9,10,11-hexahydronaphtho[1,2-b][1,4]diazepine-2,4-dione

To a pyridine solution (0.5 mL) of 5-(4-aminophenyl)-1,5,8,9,10,11-hexahydronaphtho[1,2-b][1,4]diazepine-2,4-dione (20 mg, 0.062 mmol) obtained in Example 10 was added isobutyryl chloride (10 μL, 0.093 mmol). The mixture was stirred at 80° C. for 1 hour. To the reaction mixture was added aqueous solution of hydrochloric acid under cooling in ice-bath. The mixture was stirred for 20 minutes. Insoluble was collected by filtration, and washed with water. The residue was purified by silica gel column chromatography (chloroform/methanol=99/1) to give the titled compound as white powder (23 mg, yield 95%).

¹H NMR (CDCl₃, 400 MHz) δ: 1.24 (6H, d, J=7 Hz), 1.7-2.1 (4H, m), 2.4-2.6 (1H, m), 2.6-2.8 (4H, m), 3.4-3.6 (2H, m), 6.68 (1H, d, J=9 Hz), 6.82 (1H, d, J=9 Hz), 7.12 (2H, d, J=9 Hz), 7.35 (1H, br s), 7.51 (2H, d, J=9 Hz), 7.68 (1H, s).

Example 16 5-(3-Carbamoylphenyl)-1,5,8,10-tetrahydro-1H-indeno[6,7-b][1,4]diazepine-2,4-dione

To 5-(3-cyanophenyl)-1,5,8,10-tetrahydro-1H-indeno[6,7-b][1,4]diazepine-2,4-dione (20 mg, 0.063 mmol) obtained in Example 4 was added 105% polyphosphoric acid (0.14 mL). The mixture was stirred at 115° C. for 1 hour. To the mixture was added cold water. The mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, and dried over anhydrous sodium sulfate. The solvent was removed by evaporation under reduced pressure. The residue was recrystallized from ethyl acetate-hexane to give the titled compound as slightly yellow crystal (9 mg, yield 43%).

¹H NMR (DMSO-d₆, 400 MHz) δ: 2.0-2.1 (2H, m), 2.7-3.0 (3H, m), 3.08 (1H, d, J=12 Hz), 3.1-3.3 (1H, m), 3.63 (1H, d, J=12 Hz), 6.63 (1H, d, J=8 Hz), 6.99 (1H, d, J=8 Hz), 7.3-7.5 (2H, m), 7.51 (1H, t, J=8 Hz), 7.59 (1H, s), 7.83 (1H, d, J=8 Hz), 8.03 (1H, s), 10.21 (1H, s).

Example 17 1-Acetyl-5-[3-(5-methyl-[1,3,4]oxadiazol-2-yl)phenyl]-1,5,8,10-tetrahydro-1H-indeno[6,7-b][1,4]diazepine-2,4-dione

5-[3-(5-Methyl-[1,3,4]oxadiazol-2-yl)phenyl]-1,5,8,10-tetrahydro-1H-indeno[6,7-b][1,4]diazepine-2,4-dione

By reference to synthetic example of 2-allyl-5-methyl-[1,3,4]oxadiazole [Chem Ber., 93, 2106 (1960)], 5-[3-(1H-tetrazol-5-yl)phenyl]-1,5,8,10-tetrahydro-1H-indeno[6,7-b][1,4]diazepine-2,4-dione (144 mg, 0.40 mmol) obtained in Example 5(1) was added acetic anhydride (5.8 mL), and the mixture was stirred at 100° C. for 2 hours. The mixture was cooled to room temperature. To the mixture was added cracked ice. The mixture was stirred for 30 minutes, and extracted with ethyl acetate. The ethyl acetate layer was washed with saturated aqueous solution of sodium hydrogencarbonate and then with saturated brine, and dried over anhydrous sodium sulfate. The solvent was removed by evaporation under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/hexane-1/1-3/1) to give 1-acetyl-5-[3-(5-methyl-[1,3,4]oxadiazol-2-yl)phenyl]-1,5,8,10-tetrahydro-1H-indeno[6,7-b][1,4]diazepine-2,4-dione as white powder (17 mg, yield 10%) and crude 5-[3-(5-methyl-[1,3,4]oxadiazol-2-yl)phenyl]-1,5,8,10-tetrahydro-1H-indeno[6,7-b][1,4]diazepine-2,4-dione. It was washed with ethyl acetate to give white crystal (41 mg, yield 28%).

1-Acetyl-5-[3-(5-methyl-[1,3,4]oxadiazol-2-yl)phenyl]-1,5,8,10-tetrahydro-1H-indeno[6,7-b][1,4]diazepine-2,4-dione

¹H NMR (CDCl₃, 400 MHz) δ: 2.0-2.3 (2H, m), 2.60 (3H, s), 2.69 (3H, s), 2.7-2.9 (2H, m), 2.9-3.1 (2H, m), 3.49 (1H, d, J=13 Hz), 3.88 (1H, d, J=13 Hz), 6.81 (1H, d, J=8 Hz), 7.17 (1H, d, J=8 Hz), 7.29 (1H, d, J=8 Hz), 7.49 (1H, t, J=8 Hz), 7.9-8.1 (2H, m).

5-[3-(5-Methyl-[1,3,4]oxadiazol-2-yl)phenyl]-1,5,8,10-tetrahydro-1H-indeno[6,7-b][1,4]diazepine-2,4-dione

¹H NMR (CDCl₃, 400 MHz) δ: 2.2-2.3 (2H, m), 2.60 (3H, s), 2.9-3.0 (4H, m), 3.5-3.6 (2H, m), 6.72 (1H, d, J=8 Hz), 6.96 (1H, d, J=8 Hz), 7.44 (1H, d, J=9 Hz), 7.54 (1H, t, J=8 Hz), 7.65 (1H, s), 7.84 (1H, s), 7.95 (1H, d, J=8 Hz).

Example 18 5-[3-(5-Phenyl[1,3,4]oxadiazol-2-yl)phenyl]-1,5,8,10-tetrahydro-1H-indeno[6,7-b][1,4]diazepine-2,4-dione

5-[3-(1H-Tetrazol-5-yl)phenyl]-1,5,8,10-tetrahydro-1H-indeno[6,7-b][1,4]diazepine-2,4-dione (36 mg, 0.10 mmol) and benzoic anhydride (226 mg, 1.00 mmol) were used in a process similar to Example 17 to give the titled compound as white crystal (11 mg, yield 25%).

¹H NMR (DMSO-d₆, 400 MHz) δ: 2.0-2.2 (2H, m), 2.7-3.0 (3H, m), 3.12 (1H, d, J=12 Hz), 3.1-3.3 (1H, m), 3.68 (1H, d, J=12 Hz), 6.72 (1H, d, J=8 Hz), 7.01 (1H, d, J=8 Hz), 7.40 (1H, d, J=7 Hz), 7.6-7.7 (4H, m), 7.98 (1H, s), 8.0-8.2 (3H, m), 10.24 (1H, s).

Example 19 Experimental Procedure

P2X₄ receptor antagonism of the compound of the present invention was measured as described below.

1321N1 cells stably expressing human P2X₄ receptors were plated in 96-well assay plate and cultured for 24 hours at 37° C. in an atmosphere of 5% CO₂ for intracellular calcium assay. Fura-2 AM calcium fluorescent indicator was used for the intracellular calcium assay. Fura-2 AM was dissolved in an assay buffer, and the solution was loaded onto cells. The obtained plate was used for fluorescent assay.

Test compounds were treated to cells for 15 minutes before the addition of ATP, and the response to intracellular calcium influx induced by addition of ATP was monitored by a micro plate reader. The fluorescence ratio of excitations wavelengths of 340 nm and 380 nm was used as the index of intracellular calcium change. The inhibition activities of the test compounds were calculated by comparison with the absence of the test compound (control).

(Experimental Results)

TABLE 19 Test Inhibition activities compound (IC₅₀ μM) Example 2 0.36 Example 3 3.9 Example 5 0.97

As is evident from Table 19, the compound of the present invention described in Example 2 has excellent P2X₄ receptor antagonism.

Example 20

P2X₄ receptor antagonism of the compound of the present invention was measured in the same manner as in Example 19.

The results are set forth in Table 20.

TABLE 20 Test Inhibition activities compound (IC⁵⁰ μM) Example 8 4.0 Example 9 2.6 Example 10 6.1 Example 11 3.3 Example 13 6.9 Example 14 3.8 Example 17 1.9

As is evident from Table 20, the compounds of the present invention have excellent P2X₄ receptor antagonism. 

1-22. (canceled)
 23. A diazepine derivative having the following formula (I) or a pharmacologically acceptable salt thereof:

wherein each of R¹ and R² independently is hydrogen, a C₁₋₈ alkyl group, a C₂₋₈ alkenyl group, a C₁₋₈ alkoxy group, a C₁₋₈ alkyl group having one to three halogen atoms, a C₁₋₈ alkoxy group having one to three halogen atoms, a halogen atom, hydroxyl, nitro, cyano, amino, a C₁₋₈ alkylamino group, a C₂₋₈ dialkylamino group, a C₂₋₈ acylamino group, a C₂₋₈ acylamino group having one to three halogen atoms, a C₁₋₈ alkylsulfonylamino group, carboxyl, a C₂₋₈ acyl group, an alkoxycarbonyl group comprising a C₁₋₈ alkoxy moiety, carbamoyl, a C₁₋₈ alkylthio group, a C₁₋₈ alkylsulfinyl group, a C₁₋₈ alkylsulfonyl group, or sulfamoyl; R³ is hydrogen, a C₁₋₈ alkyl group, a C₂₋₈ alkenyl group, a C₁₋₈ alkyl group having one to three halogen atoms, or a C₁₋₃ alkyl group having phenyl; each of R⁴ and R⁵ independently is hydrogen, a C₁₋₈ alkyl group, a C₁₋₈ alkyl group having one to three halogen atoms, a halogen atom, hydroxyl, nitro, cyano, amino, or a C₁₋₃ alkyl group having phenyl; R⁶ is hydrogen, a C₁₋₈ alkyl group, a C₂₋₈ alkenyl group, a C₁₋₈ alkoxy group, a C₁₋₈ alkyl group having one to three halogen atoms, a C₁₋₈ alkoxy group having one to three halogen atoms, a halogen atom, hydroxyl, nitro, cyano, amino, a C₁₋₈ alkylamino group, a C₂₋₈ dialkylamino group, a C₂₋₈ acylamino group, a C₂₋₈ acylamino group having one to three halogen atoms, a C₁₋₈ alkylsulfonylamino group, carboxyl, a C₂₋₈ acyl group, an alkoxycarbonyl group comprising a C₁₋₈ alkoxy moiety, carbamoyl, a C₁₋₈ alkylthio group, a C₁₋₈ alkylsulfinyl group, a C₁₋₈ alkylsulfonyl group, sulfamoyl, phenyl optionally having one or more substituents, or a heterocyclic group optionally having one or more substituents; the ring shown below is a five-membered to eight-membered non-aromatic ring optionally comprising one or two heteroatoms selected from N, S, and O, and being condensed with the benzene ring at the positions of 1 and 2 of the benzene ring;

the ring shown below is an aromatic ring selected from the group consisting of benzene ring, naphthalene ring, thiophene ring, pyridine ring, pyrimidine ring, indole ring, indazole ring, benzotriazole ring, benzisoxazole ring, benzimidazole ring, and quinoline ring;

Z is O or S; when X is N, Y is C═O or C═S, and the double line consisting of a solid line and a broken line is a single bond; and when X is C, Y is N, and the double line consisting of a solid line and a broken line is a double bond.
 24. A diazepine derivative having the following formula (II) or a pharmacologically acceptable salt thereof:

wherein each of R¹¹ and R¹² independently is hydrogen, a C₁₋₈ alkyl group, a C₂₋₈ alkenyl group, a C₁₋₈ alkoxy group, a C₁₋₈ alkyl group having one to three halogen atoms, a C₁₋₈ alkoxy group having one to three halogen atoms, a halogen atom, hydroxyl, nitro, cyano, amino, a C₁₋₈ alkylamino group, a C₂₋₈ dialkylamino group, a C₂₋₈ acylamino group, a C₂₋₈ acylamino group having one to three halogen atoms, a C₁₋₈ alkylsulfonylamino group, carboxyl, a C₂₋₈ acyl group, an alkoxycarbonyl group comprising a C₁₋₈ alkoxy moiety, carbamoyl, a C₁₋₈ alkylthio group, a C₁₋₈ alkylsulfinyl group, a C₁₋₈ alkylsulfonyl group, or sulfamoyl; R¹³ is hydrogen, a C₁₋₈ alkyl group, a C₂₋₈ alkenyl group, a C₁₋₈ alkyl group having one to three halogen atoms, or a C₁₋₃ alkyl group having phenyl; each of R¹⁴ and R¹⁵ independently is hydrogen, a C₁₋₈ alkyl group, a C₁₋₈ alkyl group having one to three halogen atoms, a halogen atom, hydroxyl, nitro, cyano, amino, or a C₁₋₃ alkyl group having phenyl; R¹⁶ is hydrogen, a C₁₋₈ alkyl group, a C₂₋₈ alkenyl group, a C₁₋₈ alkoxy group, a C₁₋₈ alkyl group having one to three halogen atoms, a C₁₋₈ alkoxy group having one to three halogen atoms, a halogen atom, hydroxyl, nitro, cyano, amino, a C₁₋₈ alkylamino group, a C₂₋₈ dialkylamino group, a C₂₋₈ acylamino group, a C₂₋₈ acylamino group having one to three halogen atoms, a C₁₋₈ alkylsulfonylamino group, carboxyl, a C₂₋₈ acyl group, an alkoxycarbonyl group comprising a C₁₋₈ alkoxy moiety, carbamoyl, a C₁₋₈ alkylthio group, a C₁₋₈ alkylsulfinyl group, a C₁₋₈ alkylsulfonyl group, sulfamoyl, phenyl optionally having one or more substituents, or a heterocyclic group optionally having one or more substituents; the ring shown below is a five-membered to eight-membered non-aromatic ring optionally comprising one or two heteroatoms selected from N, S, and O, and being condensed with the benzene ring at the positions of 1 and 2 of the benzene ring;

the ring shown below is an aromatic ring selected from the group consisting of benzene ring, naphthalene ring, thiophene ring, pyridine ring, pyrimidine ring, indole ring, indazole ring, benzotriazole ring, benzisoxazole ring, benzimidazole ring, and quinoline ring; and

each of Z¹ and Z² independently is O or S.
 25. A diazepine derivative or a pharmacologically acceptable salt thereof defined in claim 24, wherein R¹¹ is hydrogen, a C₁₋₈ alkyl group, a C₂₋₈ alkenyl group, a C₁₋₈ alkyl group having one to three halogen atoms, a halogen atom, hydroxyl, amino, a C₁₋₈ alkylamino group, a C₂₋₈ dialkylamino group, or a C₂₋₈ acylamino group.
 26. A diazepine derivative or a pharmacologically acceptable salt thereof defined in claim 24, wherein R¹² is hydrogen, a C₁₋₈ alkyl group, a C₁₋₈ alkoxy group, a C₁₋₈ alkyl group having one to three halogen atoms, a C₁₋₈ alkoxy group having one to three halogen atoms, a halogen atom, hydroxyl, nitro, cyano, amino, a C₁₋₈ alkylamino group, a C₂₋₈ dialkylamino group, a C₂₋₈ acylamino group, or a C₂₋₈ acylamino group having one to three halogen atoms.
 27. A diazepine derivative or a pharmacologically acceptable salt thereof defined in claim 24, wherein R¹³ is hydrogen, a C₁₋₈ alkyl group, or a C₁₋₈ alkyl group having one to three halogen atoms.
 28. A diazepine derivative or a pharmacologically acceptable salt thereof defined in claim 24, wherein each of R¹⁴ and R¹⁵ independently is hydrogen, a C₁₋₈ alkyl group, or a C₁₋₈ alkyl group having one to three halogen atoms.
 29. A diazepine derivative or a pharmacologically acceptable salt thereof defined in claim 24, wherein R¹⁶ is hydrogen, a C₁₋₈ alkyl group, a C₂₋₈ alkenyl group, a C₁₋₈ alkoxy group, a C₁₋₈ alkyl group having one to three halogen atoms, a C₁₋₈ alkoxy group having one to three halogen atoms, a halogen atom, hydroxyl, nitro, cyano, amino, a C₁₋₈ alkylamino group, a C₂₋₈ dialkylamino group, or a heterocyclic group optionally having one or more substituents.
 30. A diazepine derivative or a pharmacologically acceptable salt thereof defined in claim 24, wherein R¹⁶ is a heterocyclic group optionally having one or more substituents, said heterocyclic group being tetrazolyl, triazolyl, pyridyl, pyrazolyl, oxadiazolyl, isoxazolyl, pyrrolyl, pyrrolidinyl, imidazolyl, oxazolyl, or thiazolyl, and said substituents being selected from the group consisting of a C₁₋₈ alkyl group, a C₁₋₈ alkoxy group, a C₁₋₈ alkyl group having one to three halogen atoms, a C₁₋₈ alkoxy group having one to three halogen atoms, a halogen atom, hydroxyl, nitro, cyano, amino, a C₁₋₈ alkylamino group, and a C₇₋₈ dialkylamino group.
 31. A diazepine derivative or a pharmacologically acceptable salt thereof defined in claim 24, wherein R¹⁶ is a heterocyclic group optionally having one or more substituents, said heterocyclic group being tetrazolyl, triazolyl, pyridyl, imidazolyl, oxazolyl, or thiazolyl, and said substituents being selected from the group consisting of a C₁₋₈ alkyl group, a C₁₋₈ alkoxy group, a C₁₋₈ alkyl group having one to three halogen atoms, a C₁₋₈ alkoxy group having one to three halogen atoms, a halogen atom, hydroxyl, cyano, and amino.
 32. A diazepine derivative or a pharmacologically acceptable salt thereof defined in claim 24, wherein the ring shown below is tetrahydronaphthalene, indan, indoline, tetrahydroquinoline, or tetrahydroisoquinoline.


33. A diazepine derivative or a pharmacologically acceptable salt thereof defined in claim 24, wherein the ring shown below is benzene.


34. A diazepine derivative or a pharmacologically acceptable salt thereof defined in claim 24, wherein each of each of Z¹ and Z² is O.
 35. A diazepine derivative having the following formula (III) or a pharmacologically acceptable salt thereof:

wherein each of R²¹ and R²² independently is hydrogen, a C₁₋₈ alkyl group, a C₂₋₈ alkenyl group, a C₁₋₈ alkoxy group, a C₁₋₈ alkyl group having one to three halogen atoms, a C₁₋₈ alkoxy group having one to three halogen atoms, a halogen atom, hydroxyl, nitro, cyano, amino, a C₁₋₈ alkylamino group, a C₂₋₈ dialkylamino group, a C₂₋₈ acylamino group, a C₂₋₈ acylamino group having one to three halogen atoms, a C₁₋₈ alkylsulfonylamino group, carboxyl, a C₂₋₈ acyl group, an alkoxycarbonyl group comprising a C₁₋₈ alkoxy moiety, carbamoyl, a C₁₋₈ alkylthio group, a C₁₋₈ alkylsulfinyl group, a C₁₋₈ alkylsulfonyl group, or sulfamoyl; R²³ is hydrogen, a C₁₋₈ alkyl group, a C₂₋₈ alkenyl group, a C₁₋₈ alkyl group having one to three halogen atoms, or a C₁₋₃ alkyl group having phenyl; each of R²⁴ and R²⁵ independently is hydrogen, a C₁₋₈ alkyl group, a C₁₋₈ alkyl group having one to three halogen atoms, a halogen atom, hydroxyl, nitro, cyano, amino, or a C₁₋₃ alkyl group having phenyl; R²⁶ is hydrogen, a C₁₋₈ alkyl group, a C₂₋₈ alkenyl group, a C₁₋₈ alkoxy group, a C₁₋₈ alkyl group having one to three halogen atoms, a C₁₋₈ alkoxy group having one to three halogen atoms, a halogen atom, hydroxyl, nitro, cyano, amino, a C₁₋₈ alkylamino group, a C₂₋₈ dialkylamino group, a C₂₋₈ acylamino group, a C₂₋₈ acylamino group having one to three halogen atoms, a C₁₋₈ alkylsulfonylamino group, carboxyl, a C₂₋₈ acyl group, an alkoxycarbonyl group comprising a C₁₋₈ alkoxy moiety, carbamoyl, a C₁₋₈ alkylthio group, a C₁₋₈ alkylsulfinyl group, a C₁₋₈ alkylsulfonyl group, sulfamoyl, phenyl optionally having one or more substituents, or a heterocyclic group optionally having one or more substituents; and p is 0 or
 1. 36. A diazepine derivative or a pharmacologically acceptable salt thereof defined in claim 35, wherein R²¹ is hydrogen, a C₁₋₈ alkyl group, a C₂₋₈ alkenyl group, a C₁₋₈ alkyl group having one to three halogen atoms, a halogen atom, hydroxyl, amino, a C₁₋₈ alkylamino group, a C₂₋₈ dialkylamino group, or a C₂₋₈ acylamino group.
 37. A diazepine derivative or a pharmacologically acceptable salt thereof defined in claim 35, wherein R²² is hydrogen, a C₁₋₄ alkyl group, a C₁₋₈ alkoxy group, a C₁₋₈ alkyl group having one to three halogen atoms, a C₁₋₈ alkoxy group having one to three halogen atoms, a halogen atom, hydroxyl, nitro, cyano, amino, a C₁₋₈ alkylamino group, a C₂₋₈ dialkylamino group, a C₂₋₈ acylamino group, or a C₂₋₈ acylamino group having one to three halogen atoms.
 38. A diazepine derivative or a pharmacologically acceptable salt thereof defined in claim 35, wherein R²³ is hydrogen, a C₁₋₈ alkyl group, or a C₁₋₈ alkyl group having one to three halogen atoms.
 39. A diazepine derivative or a pharmacologically acceptable salt thereof defined in claim 35, wherein each of R²⁴ and R²⁵ independently is hydrogen, a C₁₋₈ alkyl group, or a C₁₋₈ alkyl group having one to three halogen atoms.
 40. A diazepine derivative or a pharmacologically acceptable salt thereof defined in claim 35, wherein R²⁶ is hydrogen, a C₁₋₈ alkyl group, a C₂₋₈ alkenyl group, a C₁₋₈ alkoxy group, a C₁₋₈ alkyl group having one to three halogen atoms, a C₁₋₈ alkoxy group having one to three halogen atoms, a halogen atom, hydroxyl, nitro, cyano, amino, a C₁₋₈ alkylamino group, a C₂₋₈ dialkylamino group, or a heterocyclic group optionally having one or more substituents.
 41. A diazepine derivative or a pharmacologically acceptable salt thereof defined in claim 35, wherein R²⁶ is a heterocyclic group optionally having one or more substituents, said heterocyclic group being tetrazolyl, triazolyl, pyridyl, pyrazolyl, oxadiazolyl, isoxazolyl, pyrrolyl, pyrrolidinyl, imidazolyl, oxazolyl, or thiazolyl, and said substituents being selected from the group consisting of a C₁₋₈ alkyl group, a C₁₋₈ alkoxy group, a C₁₋₈ alkyl group having one to three halogen atoms, a C₁₋₈ alkoxy group having one to three halogen atoms, a halogen atom, hydroxyl, nitro, cyano, amino, a C alkylamino group, and a C₂₋₈ dialkylamino group.
 42. A diazepine derivative or a pharmacologically acceptable salt thereof defined in claim 35, wherein R²⁶ is a heterocyclic group optionally having one or more substituents, said heterocyclic group being tetrazolyl, triazolyl, pyridyl, imidazolyl, oxazolyl, or thiazolyl, and said substituents being selected from the group consisting of a C₁₋₈ alkyl group, a C₁₋₈ alkoxy group, a C₁₋₈ alkyl group having one to three halogen atoms, a C₁₋₈ alkoxy group having one to three halogen atoms, a halogen atom, hydroxyl, cyano, and amino.
 43. A P2X₄ receptor antagonist containing a diazepine derivative or a pharmacologically acceptable salt thereof defined in claim 23, as an active ingredient.
 44. A P2X₄ receptor antagonist containing a diazepine derivative or a pharmacologically acceptable salt thereof defined in claim 24, as an active ingredient.
 45. A P2X₄ receptor antagonist containing a diazepine derivative or a pharmacologically acceptable salt thereof defined in claim 35, as an active ingredient.
 46. A preventive or therapeutic agent for neuropathic pains containing a diazepine derivative or a pharmacologically acceptable salt thereof defined in claim 23, as an active ingredient.
 47. A preventive or therapeutic agent for neuropathic pains containing a diazepine derivative or a pharmacologically acceptable salt thereof defined in claim 24, as an active ingredient.
 48. A preventive or therapeutic agent for neuropathic pains containing a diazepine derivative or a pharmacologically acceptable salt thereof defined in claim 35, as an active ingredient. 